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1 - SUMMARY
Systemic administration of cytokines such as IL-2, IL-4 and the interferons have been 
extensively examined in animal models and clinically to assess their potential as anti­
cancer drugs. To date, the promising results from animal studies have not been 
reproduced in clinical trials. The systemic administration of cytokines in cancer 
therapy is also complicated by serious side-effects because of the potency of these 
compunds. New routes of administering cytokines are therefore being investigated in 
order to prevent these side-effects and thus allow higher doses of drug to be 
administered. Routes of administration such as peritumoural, isolated limb perfusion, 
lymphokine activated killer cells and tumour infiltrating lymphocytes have all been 
tested clinically with various degrees of success.
One of the advantages that tumour cells possess is their lack of immunogenicity. It has 
been proposed that this lack of immunogenicity could perhaps be overcome by 
engineering the tumour cells to secrete cytokines thus, rendering them more 
immunogenic. A variety of tumour cell types have therefore been genetically altered 
to enable them to secrete one or more different types of cytokines. On injection of the 
cytokine-secreting tumour cells into the host animal, it has been reported that tumour 
growth may be slowed or completely prevented. One such model of cytokine- 
secreting tumour cells is the fibrosarcoma (FS-29) cell line, which has been 
genetically altered to enable it to secrete IL-2, IL-4 or IFN-y. It has been reported that 
these cells exhibit reduced tumourigenicity when injected into mice and in some cases 
the tumour cell inoculum is completely rejected.
The aim of this project was to further characterize the possible anti-tumour effects of 
the cytokine-secreting FS-29 cell-lines and to examine the possible effector 
mechanisms involved in tumour cell rejection. An immunohistochemical technique 
was developed which allowed the extent of the lymphocytic infiltration into the 
tumours that formed to be assessed. The cytokine-secreting cells were examined to
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check that they contained the appropriate retroviral integrant for one cytokine before 
they were used in any animal studies. The first study was carried out to assess the 
ability of animals to reject a two-site injection of cytokine-secreting cells. It was 
found that the IFN-y-secreting and the IL-4-secreting cells were significantly less 
tumourigenic in comparison to the non-secreting cells but only with a larger inoculum 
of cytokine-secreting cells. However, when IL-2-secreting cells were injected into 
mice, tumours grew progressively.
It has been reported that when an animal has rejected an inoculum of cytokine- 
secreting cells, a second inoculum of non-secreting cells may also be rejected. This 
rejection of tumour cells may correlate with the appearance of tumour-specific 
cytotoxic lymphocytes in the spleen. The second study examined the ability of these 
tumour-specific lymphocytes to transfer immunological memory between animals 
through the transfer of splenocytes from mice that had been previously challenged 
with tumour cells. Results from this study suggest that there may be a slight transfer 
of anti-tumour memory between animals, particularly in the group that received 
splenocytes from an animal that had previously received a small inoculum of IFN-y- 
secreting cells and did not develop a tumour.
Previous studies report that cytokine-secreting tumour cells may prevent growth of an 
equal number of admixed non-secreting tumour cells. However, few studies have been 
carried out to assess the ability of cytokine-secreting tumour cells to reduce growth of 
an already established tumour nodule. The final study was carried out to assess the 
ability of the cytokine-secreting cells alone or in various combinations to reduce 
growth of an established tumour nodule. Unfortunately, none of the cell lines, either 
alone or in combination, were able to prevent further growth of an established tumour 
nodule.
The implications of these results and their relevance to published work is discussed.
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2.1 INTRODUCTION: GENERAL
Over the past 50 years there has been a steady rise in the incidence and mortality rates 
of certain cancers. It has been reported that deaths from prostate cancer have risen 
107% between 1970 and 1990, with the overall number of registrations rising by 75% 
between 1971 and 1986 (Majeed and Burgess, 1994). In females, reports show that the 
incidence of breast cancer is 40% higher than in 1979 with the total mortality 
increasing steadily since the 1980’s. By the mid 1980's the total mortality for breast 
cancer in England and Wales was amongst the highest in the world (Quinn and Allen, 
1995). This rise in the incidence of cancer is not only confined to adults, as the 
incidence of childhood cancer, in particular central nervous system tumours, is rising 
steadily by 1% per year (Bunin et al., 1996).
However, the most alarming cancer statistic lies in the incidence of lung cancer. Lung 
cancer is the most common cause of cancer death in males and in recent years the 
incidence of lung cancer in females has risen dramatically to become the biggest cause 
of cancer death (Travis et al., 1996).
One could argue that the higher incidences of cancer could be attributed to the better 
detection techniques and the increased number of cancer screening clinics; however 
with the ever increasing mortality rates, it remains apparent that conventional cancer 
therapies such as radiotherapy, chemotherapy and surgery are insufficient to control 
the disease. In the search for more efficient therapies for cancer, the immune system 
has come under the spotlight as a possible anti-tumour therapy. The presence of an 
immune infiltration into a tumour is seen to be indicative of a vigorous inflammatory 
response and indeed, the presence of an immune infiltration has been reported to 
correlate with a better prognosis in a number of human tumours such as breast 
(Ioachim, 1976; Lauder et al., 1977). Therefore manipulating the immune system to 
respond aggressively against tumours could be of benefit therapeutically.
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2.2 Immune Surveillance Theory
The idea that the immune system may act as a surveillance mechanism against cancer 
cells was first suggested by Ehrlich in the early part of this century. It wasn't until the 
1950's that Thomas and Burnet independently proposed what later evolved as Burnet's 
immune surveillance theory. These theories, as reviewed by Kripke (1988), proposed 
that the immune system was capable of recognising cancer cells through their antigens 
and then destroying the cancer cells. This lysis of cancer cells depended upon the 
existence of an effective immune system and therefore, such lysis would not take 
place if the immune system was suppressed.
Studies on immunity against tumours induced in animals have reported that tumours 
differ greatly in their immunogenicity. For example, tumours which were induced by 
oncogenic viruses were generally found to be antigenic (Klein, 1966) whereas 
tumours which were produced through contact with chemical carcinogens although 
generally antigenic, varied in their ability to induce protective immunity (Old et al., 
1962). In contrast, spontaneous tumours, which arise in aged animals from no 
apparent cause, have been reported to be poorly or non-immunogenic (Baldwin.,
1966). Since immune surveillance as originally defined would only respond against 
highly antigenic tumours, those tumours that are non-immunogenic will not be 
recognised and destroyed by the immune system. On this basis, it would be expected 
that only highly antigenic human cancers would be subject to immune surveillance. 
However, it has been argued that highly antigenic experimental tumours in animals 
are not the same as human cancers (Hewitt et al., 1976). It is thought that human 
tumours are more likely to resemble spontanous tumours that arise in animals than 
tumours that are induced by the injection of chemical carcinogens. This theory 
therefore relies on the majority of human tumours occurring spontaneously, rather 
than from induction by viruses or chemicals. Therefore, it would appear that 
spontaneously evolving human tumours are more likely to escape immune 
surveillance.
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2.3 Immune Response to Tumours
From experimental work it would appear that there are a number of effector 
mechanisms involved in the destruction of tumour cells. Some of the main 
mechanisms are discussed below.
T-cells have been reported to be critical in the rejection of tumour cells and antigen- 
specific T-cells with antitumour activity have been generated in vitro using tumour 
infiltrating lymphocytes (TIL) extracted from melanoma (Topalian et al., 1989). T- 
cells are very much in evidence in tumours; however B lymphocytes are rarely 
observed except in melanomas (Ruiter et al., 1982). There are two main 
subpopulations of T-cells which may be distinguished according to their expression of 
CD4 or CD8 molecules. CD4+ T-cells recognise antigen associated with MHC class- 
II molecules and may act as helper T-cells (Weaver and Unanue, 1990). CD8+ T-cells 
recognise antigen associated with MHC class-I molecules and appear to mediate the 
cytotoxic destruction of cells (Yewdell and Bennink, 1992; Julius et al., 1993). As 
cytotoxic T cells are MHC class-I restricted, the levels of MHC expression may help 
determine the extent of the immune response to the tumour. Therefore, up-regulation 
of MHC molecules on tumour cells by cytokines, appears to enhance tumour 
destruction by cytotoxic T cells (Restifo et al., 1992).
Tumour infiltrations can also consist of phagocytic cells such as macrophages 
(Svennevig and Svaar, 1979). When isolated from tumour tissue these cells show 
spontaneous cytotoxic activity against tumour cells in vitro and macrophages can be 
modified to show enhanced anti-tumour activity through the administration of 
cytokines (Kos, 1989). Certain tumours such as colorectal cancer have a large 
infiltration of macrophages; however reports indicate that their presence is not always 
beneficial as macrophages can exhibit enhanced secretion of immunosuppressive 
prostaglandins which would reduce the effectiveness of the immune response
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(Maxwell et al., 1988). Prostaglandins can also be associated with tumours exhibiting 
a high metastatic potential (Rolland et al., 1980; Karmali et al., 1983).
Tumour cells have also been found to contain small numbers of natural killer cells 
(Vose and Moore, 1985). Natural killer cells (NK) are large granular lymphocytes 
which have the ability to kill tumour cells and to prevent the establishment of 
metastases (Gorelik et al., 1982). Stimulation of peripheral blood lymphocytes with 
IL-2 leads to the maturation of NK cells into lymphokine-activated killer (LAK) cells. 
These cells have been shown to be capable of lysing tumour cells in vitro (Grimm et 
al., 1982). LAK cells are discussed in detail in section 2.6.2.
Therefore, for the rejection of tumour cells to take place it would appear that the host 
must possess an effective immune system. Indeed, patients receiving 
immunosuppressive therapy following organ transplantation have a higher incidence 
of all types of malignant disease (Mihalov et al., 1996). A number of theories exist as 
to the failure of the immune response in malignant diseases. Tumour cells have been 
reported to express tumour antigens or MHC molecules therefore, failure to do so 
would result in an ineffective immune response to these tumour types. This lack of 
MHC molecules has been reported in colorectal cancers and breast cancer (Goepel et 
al., 1991). It has also been observed that some tumours contain suppressor cells which 
can inhibit the effectiveness of the immune response (Werkmeister et al., 1981). 
Reports indicate that serum from cancer-bearing patients can suppress a range of 
immune functions in normal lymphocytes. In addition, specific defects have been 
identified in lymphocytes from cancer patients, including decreased responses to IL-2 
(Monson et al., 1987). The ability of autologous tumour cells to trigger activation of 
lymphocytes but prevent their maturation into LAK cells has also indicated a tumour- 
mediated effect (Ting et al., 1987).
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2.4 Tumour Infiltrating Lymphocytes
In the mid 1970s, it was proposed that the extent of mononuclear cell (MNC) 
infiltrations into solid tumours may bear a relationship to an improved prognosis 
(Ioachim, 1976; Underwood., 1974). From an immunologic point of view, a large 
cellular infiltration into tumours may represent a strong expression of immune 
surveillance. This theory has gained support from studies by Watt and House (1978) 
and Svennevig co-workers (1984) who reported an improved prognosis in colorectal 
tumours when accompanied with a strong inflammatory response. However, these 
correlations have not been reported in all cases (Brocker et al., 1984). These 
discrepancies in correlations between patient outcome and the extent of the 
inflammatory response could perhaps be explained in that cellular infiltrations into 
tumours need not be tumour-specific and could in fact be just inflammatory cells. 
Tumour cells have been reported to have receptors for cytokines such as IL-6 and 
interferon-beta (Baldwin et al., 1989; Kimbauer et al., 1989). Since inflammatory 
cells are a possible rich source of cytokines, a strong inflammatory infiltration could 
be detrimental to the prognosis of the patient due to the many growth promoting 
properties cytokines possess (Schirrmacher, 1980). It has also been suggested that 
TILs which are present in the microenvironment may be influenced by any of the 
immunohibitory factors reported to be secreted from the tumour such as retroviral 
envelope protein pl5E (Snyderman and Cianciolo, 1984) and prostaglandins (Botha et 
al., 1986).
The intensity of MNC infiltrations and their distribution varies between tumours.
MNC are commonly found around the periphery of tumours and in the tumour stroma 
(Vose and Moore 1985; Whiteside, 1990). Squamous cell carcinomas of the head and 
neck and primary melanomas are well-infiltrated and this infiltration has been linked 
to a good prognosis in these patients (Poppema et al., 1983; Snyderman et al., 1989). 
Using immunohistological and in situ hybridization techniques, it has been possible to 
demonstrate the nature of the cellular infiltration into tumours. It has been reported
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that the majority of the infiltrating cells are T-cells (Rowe and Beverley, 1984; 
Whiteside et al., 1986) which have the the ability to lyse tumour cells in an MHC- 
unrestricted manner (Whiteside et al., 1989). Although CD3+ T-lymphocytes are the 
prominent cells present in tumours, macrophages can also be found (Svennevig and 
Svaar, 1979). NK cells have also been observed in small numbers (Vose and Moore, 
1985) and B-cells are rarely found (Ruiter et al., 1982).
Observations of the locations of T-cells in tumours have indicated that CD8+ T-cells 
are found in the parenchyma; therefore the cytotoxic T-cells are in close contact with 
the tumour cells (Vose and Moore, 1985, Cardi et al., 1989) whereas CD4+ T-cells are 
usually located in the stroma (Whiteside et al., 1987). It has been suggested that the 
CD8+ T-cell content may have an effect on prognosis in some tumours (Komstein et 
al., 1983; Vose and Moore, 1985). Studies have indicated that the ratio of CD4+ to 
CD8+ T-cells is altered due to an enhanced content of CD8+ T-cells in for example 
renal carcinomas (Finke et al., 1988), metastatic melanomas (Cardi et al., 1989), 
primary breast carcinomas (Bilik et al., 1989) and lung cancer (Rabinowich et al., 
1987).
Histological analysis of the MNC infiltrations has given an indication of state of 
activation of these cells. Many of the T-cells have been reported to be activated as 
they express HLA-DR antigens (Lopez-Nevot et al., 1986; Van Duinen et al., 1988).
In situ hybridization technology has also allowed the nature of cytokine gene 
expression to be determined (Vitolo et al., 1992) therefore giving an insight into the 
functional characteristics of these cells. Results from this study have indicated that 
TIL from squamous cell carcinomas of the head and neck expressed mRNA for TNF- 
a, IL-2 and IFN-y whereas TIL from ovarian and ductal breast tumours rarely 
expressed mRNA for any of these cytokines.
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From these reports it can be seen that with certain types of tumour, a strong 
inflammatory infiltration can indicate a better prognosis for the cancer patient. It 
would therefore be plausible that manipulating the immune response to increase the 
cellular infiltration into tumours, could lead to tumour destruction. One straight­
forward method to increase the cellular population would be to expand the cells using 
cytokines. The clinical effectiveness of such an approach is discussed in section 2.6.
2.5 Cytokines
Cytokines are a heterogeneous family of proteins which are produced by a wide 
variety of cells in the body. They have been subdivided into classes which include 
interferons, interleukins, tumour necrosis factors and chemotactic factors. Together 
they appear to regulate the magnitude and duration of the immune and inflammatory 
responses by stimulating or inhibiting the activation, proliferation and differentiation 
of various cells and by regulating the secretion of antibodies or other cytokines. 
Cytokines share a number of common characteristics in that they are all low 
molecular weight proteins (15-40KDa) which interact with high-affinity cell surface 
receptors which are specific for each cytokine. They are extremely potent substances 
with only picomolar concentrations required to mediate an effect and they have a short 
half-life ensuring that they act for a limited time. Interaction with their receptors on 
the membrane of target cells results in an altered pattern of gene expression in the 
target cell to produce the required response (Balkwill and Burke, 1989; Kroemer et 
al., 1993; Coze, 1994).
Together these responses form the complexity of the cytokine network which may 
result in either synergistic, additive or antagonistic interactions. Two CD4+ Tjq 
subsets may be distinguished by the cytokines they secrete. The cytokines produced 
by the T jjl and Tjj2 subsets exhibit cross-regulation in that cytokines secreted by one 
subset appear to block the production or activity of the cytokines secreted by the other 
subset. Tpjl cells appear to produce predominantly IL-2, IFN-y and TNF while in the
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case o fT H2 clones, IL-4, IL-5, IL-6 and IL-10 (Mosmann et al., 1989; Cherwinski et 
al., 1989). It would appear that IFN-y secreted by the T jjl subset preferentially 
inhibits the proliferation of the Tjj2 subset (Gajewski and Fitch, 1988) and IL-10 may 
down-regulate the secretion of IFN-y and IL-2 (Moore et al., 1990; Vieira et al.,
1991). More recently, IL-12 has been reported to augment the generation of Tj-fl cells 
(Trinchieri, 1993). IFN-y and IL-2 appear to promote IgG2a production by B-cells 
early in their activation, but inhibit IgGl and IgE production (Snapper et al., 1988a). 
In contrast IL-4 secreted by the Tyf i  subset promotes production of IgGl and IgE and 
appears to suppress the production of IgG2a (Snapper et al., 1988b).
Therefore, it would appear with reference to cytokine production by T-lymphocytes 
there is a complex system of regulation which limits the inflammatory response. In 
general an acute inflammatory response is transient but, in some cases persistant 
immune activation can occur, resulting in pathologic consequences. The cytokines 
produced during an inflammatory reaction such as IL-1, TNF-a (Evans et al., 1989) 
and IL-6 (Snick, 1990) can ultimately lead to tissue damage if continually produced. 
This type of damage can be observed in diseases such as rheumatoid arthritis where 
excess TNF-a is reported to be a pivotal molecule in the disease progression 
(Leirisalo Repo et al., 1995) which has led to the initiation of clinical trials using an 
antibody to TNF-a (Lorenz et al., 1996). Raised pro-inflammatory cytokines such as 
TNF-a and IL-6 have been detected in the epithelium and lamina propria of patients 
with coeliac disease and is thought to play a role in the pathogenesis of this disorder 
(Przemioslo et al., 1994). There is also evidence that pro-inflammatory cytokines are 
implicated in a variety of other diseases such as peptic ulcers (Muller and Hunt,
1993), ankylosing spondilitis (Gratacos et al., 1994), Alzheimer's disease (Mrak et al., 
1995), multiple sclerosis (Patterson, 1995) and myasthenia gravis (Link, 1994). It has 
been reported that serum levels of cytokines such as IL-1, IL-6 and TNFa are higher 
in cancer patients (Bauer and Herrman, 1991; Mantovani et al., 1994) and some 
studies demonstrate that high levels of serum cytokines may promote the mechanisms
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involved in the pathogenesis of neoplastic cachexia (McNamara et al., 1992; 
Strassmann et al., 1992).
From these reports it could be concluded that cytokines are potent mediators of the 
inflammatory response. Therefore their ability to evoke aggressive anti-tumour 
responses is currently being thoroughly investigated. The clinical effectiveness of 
cytokines as possible anti-tumour agents is discussed in section 2.6.
2.6 Clinical Effectiveness of Cytokines
2.6.1 Interferons
The interferons were the first cytokines to be discovered and these were originally 
thought to be a single substance, but they are now recognised to be a group of proteins 
and glycoproteins which can be subdivided according to their differences in their 
antigenic, biologic and chemical properties (Rubin et al., 1980). The three types of 
interferons a , p and y. IFN-a and IFN-p (Type-I) are stable at acid pH and may be 
induced in a wide range of cell types to activate cells by binding to a common 
receptor. IFN-y (Type-II) appears to be induced in T-lymphocytes and may be 
neutralised at acid pH. It reportedly activates cells via a different receptor (Chebath et 
al., 1987). Together, the interferons have been reported to possess a range of 
biological properties such as antiviral, antiproliferative and immunomodulatory 
activities (Petska et al., 1987).
In 1980, Gutterman reported that a partially-purified preparation of IFN-a could 
induce regression of tumours and established metastasis in patients with breast 
carcinomas or well-differentiated B-cell neoplasms. To date, clinical trials have 
reported that IFN-a has been effective in the treatment of a range of neoplasms such 
as hairy-cell leukaemia (Quesda et al., 1984). The receptor for the type-I interferon 
has been demonstrated in neoplastic cell lines such as leukaemic cells from hairy-cell 
leukaemia (Platanias et al., 1992). IFN-a does not cure hairy-cell leukaemia, and up to
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50% of patients will relapse after treatment discontinuation (Quesda et al., 1984). 
However, most relapsed patients will respond to retreatment with IFN-a, and it has 
been reported that continuous administration of IFN-a may prolong survival to 6 
years in 82% of patients (Smith et al., 1991).
IFN-a has also been reported to induce haematological remission in patients with 
chronic myelogenous leukaemia (Talpez et al., 1983). Administration of IFN-a has 
been reported to eliminate Philadelphia-positive cells from the bone marrow of 
patients with chronic myelogenous leukaemia (Talpez et al., 1986). A recent clinical 
trial to test the effectiveness of IFN-a with chemotherapeutic agents reported that 
IFN-a in combination with Busulphan or Hydroxurea was effective in prolonging the 
median survival of patients with chronic myelogenous leukaemia from 41 months to 
61 months (Allan et al., 1995).
Treatment of multiple myeloma using IFN-a has been reported to be effective. 
However, the response rates of multiple myeloma to chemotherapeutic agents is 
reported to be greater; therefore IFN-a has been used as an adjunct to chemotherapy 
for multiple myeloma in order to increase the response rate to chemotherapy 
(Montuoro et al., 1990). IFN-a may also be administered as a maintenance therapy for 
multiple myeloma following induction therapy with combined chemotherapy 
(Mandelli et al., 1990). IFN-a in combination with cytotoxic chemotherapy was also 
reported to prolong the time to treatment failure, and the duration of the complete 
response in patients with clinically aggressive, low grade and certain histological 
variants of intermediate-grade non-Hodgkin's lymphoma (Smalley et al., 1992).
As well as leukaemias, the interferons have also been reported to induce responses in 
some solid neoplasms. A response rate of up to 20% was reported when IFN-y was 
administered for renal cell carcinoma (Recombinant Human Interferon-y Research 
Group, 1987). The combination of IFN-a with IL-2 has resulted in greater response
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rates than IFN-y alone for the treatment of renal cell carcinoma and malignant 
melanoma. Rosenberg (1989a) and co-workers reported response rates of 43% with 
the combination of IL-2 and IFN-a for renal cell carcinoma and malignant melanoma. 
Similar results have also been reported by Kirchner and colleagues (1990). As these 
tumours are not responsive to chemotherapy, IL-2 and IFN-a in combination is 
currently the treatment of choice for these neoplasms.
IFN-a in combination with 5-fluorouracil was reported to increase the response rate 
relative to 5-fluorouracil alone for the treatment of disseminated colorectal cancer 
(Wadler et al., 1989). In vitro studies demonstrated that cytotoxicity was greater when 
5-fluorouracil was combined with Leucovorin and IFN-a in several cell lines 
(Rastum, 1991). Partial responses using this combination have been reported in half of 
the patients with adenocarcinomas of gastrointestinal or unknown primary or 
neuroendocrine tumours (Seymour et al., 1994). Administration of IFN-a with 5- 
fluorouracil and cisplatin for the treatment of oesophageal carcinoma has resulted in 
major response rates in half of the patients, although this was with severe toxicity 
(Ilson et al., 1995). However, IFN-a in combination with cisplatin and 5-fluorouracil 
for the treatment of recurrent or metastatic head and neck cancer, resulted in poor 
response rates which were again associated with severe toxicity (Cascinu et al., 1994).
As discussed previously in this section, IFN-y reacts with a different cell surface 
receptor than IFN-a and IFN-(3, therefore it was proposed that IFN-a or IFN-P in 
combination with IFN-y may potentiate the anti-tumour activity of the interferons. 
However, the addition of IFN-y to IFN-a was not reported to improve the response 
rate of IFN-a for the treatment of renal cell carcinoma, and the combination may have 
been antagonistic to the efficacy of IFN-a (Demulder et al., 1995).
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2.6.2 Interleukin-2 and LAK Cells
Interleukin 2 is a lymphokine produced by T-lymphocytes after antigen or mitogen 
stimulation (Smith, 1988). IL-2 was originally called T-cell growth factor because it 
was reported to to sustain the growth and proliferation of T-cells (Morgan et al.,
1978). It has now been renamed because it appears to have effects on the proliferation 
and function of immunological cells such as T-lymphocytes (Robb, 1984) natural 
killer (NK) cells (Henney et al., 1981) and B-cells (Gordon and Guy, 1987). There 
have been two approaches to the administration of IL-2. The first route is that of bolus 
injection or continuous systemic administration. The second approach, which Lotze 
and his co-workers described in 1981, is that of adoptive therapy, which is the 
systemic transfer of immunologic reagents appearing to possess anti-tumour activity. 
Lotze reported that peripheral blood mononuclear cells (PBMC) from normal 
individuals and cancer patients could be activated in vitro using IL-2 and the cells 
generated were capable of killing fresh tumour target cells, but not normal cells. The 
cells with lytic activity were referred to as lymphokine activated killer cells (LAK). 
Experimental studies in this area were facilitated by the cloning of the IL-2 gene and 
its insertion into E. coli (Rosenberg et al., 1984). Therefore, large amounts of highly 
purified IL-2 with full biological activity were available for use in animal and human 
studies.
There have been numerous clinical trials using IL-2 and IL-2/LAK cells. The first of 
this type was carried out by Rosenberg and colleagues in 1985 at the National Cancer 
Institute (NCI) with a follow-up report in 1987. 157 patients with metastatic cancer 
for whom standard therapy had proved ineffective were treated with LAK cells plus 
IL-2 or high dose IL-2 alone. Of 106 patients receiving LAK cells plus IL-2, 8 were 
reported to have complete responses , 15 had partial responses and 10 had minor 
responses. Of 46 evaluable patients treated with high-dose IL-2 alone, 1 had a 
complete response, 5 had partial responses, and 1 had a minor response.
26
Approximately one-third of patients receiving LAK/IL-2 therapy had an anti-tumour 
response but IL-2 alone produced only half of that response.
In 1989, Rosenberg and co-workers (1989b) carried out further trials with IL-2 for the 
treatment of cancer patients which demonstrated the type of carcinoma that appeared 
to be responsive to IL-2 or IL-2/LAK therapy. With IL-2 alone some responses were 
reported with melanoma and renal cell carcinoma. However, no responses were 
observed with colorectal cancer, non-Hodgkin's lymphoma or breast cancer. 
Furthermore, treatment with LAK/IL-2 produced greater responses in melanoma and 
renal cell carcinoma compared to IL-2 alone and responses were also reported with 
non-Hodgkin's lymphoma and colorectal cancer which were not observed with IL-2 
alone.
A more recent trial administering IL-2 with and without LAK cells reported improved 
long-term survival after intracavitary injection of IL-2 and LAK cells for adults with 
recurrent malignant glioma. LAK cells and IL-2 were reported to be administered 
safely within the CNS, resulting in improved long-term survival in patients with 
recurrent glioblastoma. This increased survival was apparently associated with 
significant biologic changes such as an eosinophil and lymphocyte infiltration (Hayes 
et al., 1995) A phase-III randomised trial of IL-2 with or without LAK cells was 
carried out in patients with advanced renal cell carcinoma (Law et al., 1995).
However, there appeared to be no differences between the two treatment arms with 
there being no reports of increased response rates or greater length of survival with the 
addition of LAK cells to IL-2. When IL-2 was administered alone there appeared to be 
a low level of anti-tumour immunity which did not appear to be enhanced by the 
addition of LAK cells (Law et al., 1995).
There are many problems associated with the use of IL-2 alone or in combination with 
LAK cells. Firstly the use of LAK cells is expensive and the culture of lymphocytes
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from patients is time-consuming. Secondly, the toxicity of IL-2 is a major problem 
(discussed in section 2.7). In order to avoid the toxicity associated with IL-2, low-dose 
IL-2 has been combined with cyclophosphamide (Mitchell et al., 1988) or dacarbazine 
(Flaherty et al., 1988). The response rate of this combination was reportedly greater 
than IL-2 administered alone. During the combination treatment with IL-2 and 
cyclophosphamide, induction of LAK cell activation was reported in all responding 
patients, and none of the patients without LAK activation was reported to have a 
remission from their disease (Mitchell et al., 1988).
Another approach is to use TIL rather than LAK cells to induce cytotoxic cells by IL- 
2. In 1986, Rosenberg and his group reported that TIL derived from murine tumours 
and grown in rIL-2 were 50-100 times more effective than LAK cells in eradicating 
established pulmonary or liver metastasis in a murine sarcoma model. Based on these 
observations, clinical trials of TIL were initiated. Results of early clinical trials using 
TILs were encouraging (Rosenberg et al., 1988). However, recent reports have not 
supported these results. In 1995, a phase-I trial of repeated TIL infusion was reported 
(Ravaud et al., 1995). This trial was not a success with no objective responses against 
melanoma being observed. Treatment was also complicated by a variety of side- 
effects which could perhaps be related to the increase in plasma tumour necrosis 
factor levels. Furthermore, the use of TILs is limited because of difficulties in 
obtaining TIL from tumours. Once obtained, the TIL then have to be grown for 4-5 
weeks to obtain therapeutic quantities which may prove an unacceptable length of 
time for patients with advanced cancer.
2.6.3 Interleukin-4
IL-4 is reported as having stimulatory effects on the function of a number of 
leukocytes including having B and T-cell regulatory functions (Howard et al., 1982; 
Mitchell et al., 1989). Therefore, there has been some interest in its therapeutic 
potential in vitro and in vivo.
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Several laboratories have reported that IL-4 inhibits the in vitro growth of a variety of 
neoplasms such as, renal cell carcinoma (Hoon et al., 1991a), melanoma (Hoon et al., 
1991b), oestrogen-dependant breast cancer (Toi et al., 1992), non-Hodgkin's 
lymphoma (Defrance et al., 1992), non-small cell lung carcinomas (Topp et al., 1993), 
head and neck carcinomas (Topp et al., 1995) and glioblastomas (Topp et al., 1994). 
Reports have also indicated that the receptor for IL-4 is detectable on some tumours 
such as colon and lung cancer (Al Jabaari et al., 1989).
Data from clinical trials of IL-4 for the treatment of different neoplasms has resulted 
in conflicting reports. Preliminary data from phase-I trials reported clinical responses 
in patients with chronic lymphocytic leukaemia and low-grade lymphomas (Maher et 
al., 1990). However a phase-II trial of IL-4 for patients with metastatic melanoma or 
and advanced renal carcinoma proved to be unsuccessful (Margolin et al., 1994). 
Margolin and co-workers reported that one of the 30 patients with metastatic 
melanoma had a complete response following treatment with IL-4 and none of the 19 
patients with advanced renal cancer was reported to have any response to IL-4 
therapy.
From these studies it appears that IL-4 does not have substantial anti-tumour activity 
in humans; however IL-4 combined with IL-2 has been suggested as possibly having 
greater therapeutic potential as it has been reported to stimulate the proliferation of T- 
cells activated by exposure to IL-2 (Kawakami et al., 1988). IL-4 has also been 
reported to stimulate peripheral blood mononuclear cells in vitro from patients with 
solid tumours treated with IL-2 (Treisman et al., 1990) and to enhance antibody- 
dependant cellular cytotoxicity mediated by peripheral blood mononuclear cells and 
lymphocytes (Wersall et al., 1991). It appears to be important that LAK cell activity is 
first preactivated in vitro or in vivo with IL-2 (Higuchi et al., 1989), since IL-4 alone 
does not produce LAK cell activity and may inhibit LAK cell induction if cells are 
exposed to IL-4 before IL-2 (Spits et al., 1988).
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2.6.4 Tumour Necrosis Factor
Tumour necrosis factor has been extensively tested in clinical trials in a variety of 
routes, doses and schedules. However reports are disappointing in that TNF appears to 
have little anti-tumour activity when administered systemically (Table 1, Kunkel et 
al., 1992). Naylor and co-workers (1990) reported that half of the ovarian cancers they 
studied appeared to be transcribing the TNF gene. They proposed that if tumour cells 
have the ability to produce TNF, the production could contribute to neoplastic 
progression and alter the response to therapy.
Table 2.1 - Clinical Trials of Recombinant Human Tumour Necrosis Factor
TNF Dose Route Schedule No. of 
Patients
Complete
Response
Partial
Response
1-48 x 104
units/m^
lh, IV 
infusion
Every 3 
weeks
29 0 0
4.5-645
ug/m^
24h, IV 
infusion
Every 3 
weeks
50 0 1
5-200 ug/m2
30 mins IV 
infusion
Days 1-5 
every 3 
weeks
27 0 l
5-200 ug/m^ IM
Days 1-5 
every 2 
weeks
19 0 0
40-400ug/m^
24h, IV 
infusion
Once or twice 
weekly
15 0 0
5-150 ug/m^ SC
Days 1-5 
every other 
week
9 0 0
683-956
ug/m^
30-60 mins 
IV
Every other 
week
22 0 0
5-250 ug/m^
30 mins and 
4h, IV
Days 1-5 
every 2 
weeks
39 0 0
5 x  104- 
3 x 105
units/m^
5 day
continuous IV 
infusion
Every 4 
weeks
19 0 0
(Kunkel et al., 1992)
It also appears that the efficacy of TNF is not improved when administered 
systemically in combination with other cytokines. For example TNF was combined
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with IFN-y for the treatment of metastatic melanoma (Retsas et a l, 1989). Reports 
from this study indicate that TNF and IFN-y have no activity against tumour growth 
when administered together and that the toxicity associated with TNF was 
considerable. The results from the clinical trials with TNF have been disappointing 
considering the success of the animal experiments (Havell et al., 1988; Tomazic et al., 
1988). One of the limiting factors in the administration of TNF in humans is that the 
cytokine is associated with considerable toxicity (discussed in section 2.7).
2.6.5 Interleukin-1
Interleukin-1 is reported to be an important mediator in the immune system in that, it 
appears to control haematopoesis and may be capable of inducing the release of IL-2 
and other cytokines from activated lymphocytes (Dinarello, 1988). IL-1 has been 
reported to have antitumour activity in murine tumour models when administered 
alone (Johnson et al., 1991) or in combination with other cytokines (Brunda et al., 
1994). In the latter study, activity of IL-1 was reported to be enhanced by the addition 
of IFN-a.
The results from the above animal studies are similar to the results of IL-1 therapy in 
clinical trials in that when IL-1 was administered alone, there appeared to be little 
anti-tumour activity (Redman et al., 1994), but a trial of IL-1 in combination with 
another cytokine was reported as being more encouraging (Triozzi et al., 1995). 
Triozzi and co-workers combined IL-1 with IL-2 which appeared to result in a marked 
activation of T-cells and LAK cells. In addition, there appeared to be objective anti­
tumour responses, including a complete response in a patient with colon cancer 
metastatic to the liver.
One of the major complications limiting the dose intensity of chemotherapy is 
myelosupression (section 2.7). Since IL-1 is reported to be a major co-ordinator of the 
haematopoietic system, it was proposed that if IL-1 was administered in combination
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with chemotherapy, this myelosupression could be reduced or prevented. Clinical 
trials have been carried out to evaluate the ability of IL-1 to protect patients from 
chemotherapy induced myelosuppression. In one trial, 18 patients with colon cancer 
consecutively received IL-1 p alone followed by chemotherapy with 5-FU alone, 
followed by 5-FU combined with IL-1 in consecutive cycles of therapy (Crown et al.,
1991). Reports from this study indicate that patients developed only a transient 
neutropenia, monocytopenia, lymphopenia and they also appeared to develop an 
increase in their platelet count. Another aspect to this type of therapy is that it may 
allow for administration of higher doses of chemotherapy without the fear of 
myelosuppression.
2.6.6 Interleukin-6
Interleukin-6 may help in the regulation of the expression of other cytokines, and it 
has been reported to stimulate effector cells to produce antitumour effects in murine 
tumour model systems when administered both systemically and locally (Borden et 
al., 1994; Mule et al 1990). However, in phase-I/II trials of human malignancies, little 
evidence of antitumour activity was noted (Weber et al., 1994, Van Gameren et al., 
1994; Weiss et al., 1995). Additionally, IL-6 may have a role in the growth or 
behaviour of a number of tumours, including myeloma, ovarian cancer, and 
mesothelioma, although the exact nature remains controversial (Ballester et al., 1994; 
Monti et al., 1994; vander Zee et al., 1995).
2.6.7 Other Uses of Cytokines In Cancer Therapy - The Colony Stimulating Factors 
Interleukin-3, granulocyte-colony stimulating factor, granulocyte-monocyte 
stimulating factor and monocyte-stimulating factor have been classified as colony 
stimulating factors. Among these CSF's, recombinant GM-CSF and recombinant G- 
CSF have been approved for clinical use in patients in association with chemotherapy 
in order to prevent or decrease the severity of chemotherapy-induced neutropenia. 
Clinical trials of GM-CSF and G-CSF performed on cancer patients with associated
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chemotherapy-induced neutropenia demonstrated that neutropenia was significantly 
less severe and shorter in the cycles with CSF's as compared with those without 
(Antman et al., 1988; Shulz et al., 1991; Morstyn et al., 1988; Gabrilove et al., 1988; 
Bronchud et al., 1989). The frequency of infectious complications was also reported 
to be significantly reduced following administration of CSF's in these trials and 
patients needed fewer days of antibiotic treatment. Addition of CSF's to the regimen 
appear to allow higher doses of chemotherapy to be administered.
Preliminary clinical trials have reported that the CSF IL-3 may increase peripheral 
blood thrombocytes and accelerate the recovery from chemotherapy-induced 
thrombocytopenia (Stahl et al., 1992). Recombinant human IL-3 has also been 
reported to dose-intensify the chemotherapeutic agents carboplatin and 
cyclophosphamide in a phase-I trial for the treatment of epithelial ovarian cancer 
(Veldhuis etal., 1995).
2.7 Side-Effects Of Cytokine Therapy
One of the major problems in the use of cytokine therapy is the toxicity of these 
compounds which may result in the patient suffering serious side-effects. Therefore, 
cytokines have to be administered in low-doses to prevent these side-effects which in 
turn, may reduce their efficacy as anti-cancer agents. Fever, chills, fatigue and other 
flu-like symptoms are common place in patients undergoing cytokine therapy. These 
symptoms are thought to result from the elaborate cascade of secondary cytokines 
such as IL-1 and TNF which are commonly produced with cytokine therapy (Gemlo 
etal., 1988).
One of the most serious side-effects associated with cytokine therapy, particularly 
with IL-2, TNF and IL-1 is hypotension (Gaynor and Fisher, 1993). This hypotension 
appears to be the result of cytokine-induced vasodilation. Marked reductions in 
systemic vascular resistance were observed within two hours of an IL-2 injection
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(Gaynor and Fisher, 1993; Lee et al, 1989), an effect which appeared to be mediated 
by the vasodilator, nitric oxide (Lowenstein and Snyder, 1992).
Administration of cytokines such as IL-2 and IL-4 appears to result in an increased 
vascular permeability which may result in extravasation of plasma into the tissues 
therefore leading to weight gain, oedema, pleural effusions and ascites (Mier, 1993; 
Atkins et al., 1992). Complement activation is also thought to contribute to this 
vascular leak syndrome as high levels of the complement pathway fragment C3a, 
appear to be detected in the plasma of patients receiving IL-2. The levels of which 
appeared to correlate with the extent of the vascular-leak syndrome (Vachino et al., 
1991; Thijis et al 1990).
Higher rates of bacterial infection have been reported in patients undergoing IL-2 
therapy (Snydman et al., 1990), which is thought to be due to an acquired defect in 
neutrophil function (Klempner et al., 1990). It is proposed that this chemotactic defect 
in neutrophil function is the result of endogenous TNF production in patients treated 
with IL-2, since a similar defect has been observed by exposing neutrophils to TNF in 
vitro (Atkinson et al., 1988).
Treatment of cancer patients with IL-2 or IFN-a has been reported to result in the 
development of autoimmune hypothyroidism (Fentiman et al., 1985; Atkins, 1993). 
Examination of thyroid aspirates from patients treated with IL-2 or IFN-a has 
demonstrated an extensive infiltration of lymphocytes (Pichert et al., 1990; Karlsson 
et al., 1991). Therapy with IL-2 and IFN-a may also result in side-effects which are 
similar to rheumatoid arthritis (Massarotti et al., 1992) and Crohn's disease (Sparano 
etal., 1993).
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Other common side-effects associated with cytokine therapy include, disorientation 
and confusion with IL-2 therapy (Denicoff et al., 1987) and depression and 
myelosuppression with high-dose IFN-a therapy (Spiegal, 1987).
Together these systemic side-effects limit the dose of cytokines that may be safely 
administered to cancer patients and therefore potentially reduce their maximum 
possible efficacy. Therefore, alternative means of delivering these cytokines have 
been proposed in order to reduce their toxicity. The administration routes of local 
cytokine therapy and cytokine gene therapy have come under intense investigation 
over the past few years in a bid to improve the immunotherapy of cancer.
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2.8 Local Administration of Cytokines
One of the methods investigated in order to avoid toxicity of cytokines has been their 
local administration. Bosco and colleagues reported that when IL-4 was administered 
subcutaneously around tumour-draining lymph nodes of a chemically-induced 
fibrosarcoma (CE-2) and a spontaneous adenocarcinoma (TS/A) in BALB/c mice, the 
tumour growth was inhibited (Bosco et al., 1990). It also appeared that this therapy 
with IL-4 could lead to a state of long lasting immune memory in that, growth of a 
second contralateral tumour challenge was reported to be significantly impaired. IL-4 
appeared to be more effective than other cytokines such as, IL-2, IL-1 p and IFN-y in 
producing an anti-tumour response and the combination of cytokines did not result in 
an additive anti-tumour response. However, the establishment of a tumour-specific 
memory appeared to be enhanced with the combination of IL-4 and IL-1 p. Analysis of 
the possible effector mechanisms responsible for the anti-tumour response 
demonstrated that CD4+ T-cells appeared to be important (Bosco et al., 1990). This 
approach could be of use clinically as the perilymphatic injection of cytokines could 
be easily performed around tumour draining lymph nodes of many cancer patients. 
Furthermore, the response to this cytokine therapy appeared to be immediately local, 
which may reduce the side-effects associated with cytokine therapy.
Peritumoural injections of cytokines is another approach that has been attempted in 
order to reduce the toxicity and improve the efficacy of cytokine therapy (Gallagher 
and Zaloom, 1992). When IL-4 was injected into a B.16 melanoma which had been 
induced in C57BL/6 mice, it appeared that IL-4 could inhibit tumour growth and in 
some animals result in a complete tumour regression. In addition, local administration 
of IL-4 appeared to result in a systemic immune response in that, when mice were 
innoculated with tumour cells in the neck and in the thigh, peritumoural treatment 
with IL-4 at the neck site appeared to result in tumour regression at both sites 
(Gallagher and Zaloom, 1992). Following these observations, combination therapy of 
cytokines was carried out in the same tumour model (Zaloom and Gallagher, 1993).
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When IL-4 and IL-2 were administered together, IL-2 appeared to antagonise the anti­
tumour effect of IL-4 alone, and IL-2 alone, or in combination with IL-4, was not 
reported to induce a systemic protection as had been reported with IL-4 alone. 
Peritumoural injections of cytokines is another method which may be easily 
performed clinically for the treatment of cancer patients, although the site of the 
tumour would have a bearing on the feasiblity of this treatment.
Clinical trials have been carried out to assess the efficacy of local administration of 
cytokines such as, the perilymphatic administration of IL-2 for head and neck cancer 
(Whiteside et al., 1993) and the intralesional treatment of melanoma with TNF and 
IFN-y (Retsas et al., 1989). These trials have had little success. Perhaps the most 
encouraging responses observed with local therapy is the use of TNF in isolated limb 
perfusion for melanoma. It has been reported that high dose TNF-a with IFN-y and 
melphalan for stage-III melanoma may be administered successfully with little 
toxicity. In this trial, 90% of patients experienced a complete remission and 10 % of 
patients were reported to have a partial response from their disease with a median 
survival of 28 months. Similar results were reported with TNF-a and melphalan using 
isolated limb perfusion again for melanoma. In seven of the nine patients studied, 
sloughing and necrosis of the superficial tumours were apparent within 48 hours of 
perfusion and all patients experienced a complete tumour response. There were no 
systemic side-effects but local side-effects such as oedema and joint stiffness were 
pronounced in some patients (Hill et al., 1994).
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INTRODUCTION: CYTOKINE GKNR CELL THERAPY OF CANCER
3.1 Introduction
Thre is another approach to deliver cytokines locally in order to improve efficacy and 
avoid toxicity. This is to use tumour cells that have been genetically engineered to 
secrete cytokines. It has been proposed that the presence of cytokine-engineered 
tumour cells may render the cells more immunogenic and therefore enhance their 
recognition, signalling the immune system to respond more vigorously to a poorly or 
non-immunogenic carcinoma.
The first experiment of this type was carried out by Tepper and co-workers in 1989. 
His strategy involved transfecting and expressing the IL-4 gene into the J558L 
plasmacytoma and the K485 adenocarcinoma cell-lines. These cells were then injected 
alone or mixed with non-transfected tumour cells into T-cell deficient (nu/nu) mice 
and their growth monitored. It was found that the control plasmacytoma cells formed 
very large tumours only 8-10 days after injection, however, the IL-4 expressing 
plasmacytoma line did not form tumours in over 100 days of observation. The results 
also suggested that the presence of the IL-4 gene substantially reduced tumour growth 
in the adenocarcinoma cell-line. When IL-4 secreting cells were mixed with non­
secreting cells and injected into mice, there was again no tumour formation. 
Furthermore, as there was no tumour growth in nude mice, it may be concluded that 
T-cells were not an important effector mechanism for the tumour cell rejection. 
Histological examination of the injection site showed that this anti-tumour effect 
appeared to be mediated by a cellular infiltration composed of eosinophils and 
macrophages.
It was the result of this study that triggered extensive research into gene therapy of 
cancer using cytokines. The use of cytokine-secreting cells has been successful in a 
number of animal models (detailed in the following chapter) and, has given an insight 
into the many possible effector mechanisms involved in tumour cell destruction.
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3.2 Cvtokine Gene Cell Therapy Using IL-2
Perhaps the most extensively studied cytokine for gene transfer has been IL-2. To 
date, IL-2 has been successfully transferred into a variety of tumour models and has 
given an insight into the many possible effector mechanisms involved in tumour cell 
destruction. For example, the gene for human IL-2 has been introduced into CMS-5 
cell line, which is a weakly-immunogenic mouse fibrosarcoma cell-line (Gansbacher 
et al., 1990a). Injection of these cells into mice resulted in a decreased 
tumourigenicity and protection from a subsequent challenge with CMS-5 cells. When 
IL-2 producing CMS-5 cells were co-injected with unmodified tumour cells, tumour 
formation was again prevented. This protective response against the parental tumour 
cells correlated with the appearance of tumour-specific cytotoxic T cells in the animal 
spleens indicating that these cells may be responsible for the rejection of tumour. 
Decreased tumourigenicity by insertion of the IL-2 gene has also been reported in a 
variety of other models such as HSNLV (a rat sarcoma cell line) clones which were 
induced to secrete different amounts of IL-2 (Russell et al., 1991). The IL-2 secretion 
of this cell line resulted in a reduced tumourigenicity and metastatic potential in rats, 
which was associated with a CD4+ and CD8+ T cell lymphocytic infiltration. 
However, when the growth of IL-2 secreting cells in T-cell deficient nu/nu rats was 
slowed, this pointed to the involvement of another non-T-cell effector mechanism 
(Russell et al., 1991). This theory was confirmed when IL-2 was introduced into the 
non-immunogenic spontaneous adenocarcinoma TS/A cell line (Cavallo et al., 1992). 
When these cells were injected into mice, the high-secreting IL-2 clones were quickly 
rejected. This rejection was associated with a neutrophil infiltration, with a smaller 
CD8+ T-cell infiltration. NK cells and CD4+ T-cells appeared not to have a role in 
tumour rejection but the neutrophil-dominated rejection appeared to require CD4+ 
lymphocytes to have a persistant tumour-specific memory (Cavallo et al., 1992).
A further effector mechanism for IL-2 was observed when the cDNA for human IL-2 
was introduced into the human renal cancer cell line SK-RC-29 cells (Gastl et al.,
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1992). When injected into BALB/c mice, the SK-RC-29 IL-2 secreting cells showed 
no visible tumours at the injection site when examined macroscopically. However 
further examination of the injection site in these animals revealed small tumour cell 
aggregates which, by immunohistology, revealed a strong peritumoural infiltration of 
peroxidase positive cells, the majority of which appeared to be macrophages.
However macrophages appeared not to be the effector cells involved when the non- 
immunogenic murine fibrosarcoma MCA 102 cell line was transduced to secrete IL-2 
(Karp et al., 1993). These cells failed to grow when injected into C57BL/6 mice. This 
inhibition of growth was halted when CD8+ T-cells or NK cells were depleted, but 
not when CD4+ T-cells were depleted. However, when the IL-2 secreting cells were 
mixed with parental tumour cells, the growth of the tumour was delayed and 
histologic analysis revealed a dense lymphocytic infiltration of CD4+ and CD8+ T- 
cells (but not macrophages) into these tumours (Karp et al., 1993).
An involvement of NK cells was also observed when murine MBT-2 cells (derived 
from a carcinogen-induced bladder tumour) were transfected with IL-2 (Saito et al., 
1994). These cells were rejected when injected into mice and also when injected into 
nu/nu mice. Therefore, T-cells appeared not to be the main effector mechanism 
involved, although histological analysis revealed that CD4+ and CD8+ T-cells were 
present at the site of injection of the IL-2 secreting cells. However, with the cells at 
the injection site, there also appeared to be large numbers of NK cells. As T-cells 
appeared not to be responsible for the tumour cell rejection, this would suggest that 
NK cells may have been an important effector mechanism (Saito et al., 1994).
It has been reported that a variety of effector mechanisms are required for the rejection 
of IL-2 secreting J558L cells (Hock et al., 1993). Cell depletion experiments indicate 
that CD8+ T-cells were required for complete long-term tumour rejection, although 
transient tumour suppression was observed in the absence of CD8+ T-cells. However,
40
NK cells were also involved in the anti-tumour response and histological analysis 
revealed a heavy infiltration of macrophages (Hock et al., 1993).
3.3 Gene Cell Therapy Using Combinations of Cytokines
From the above, it is clear that the effector mechanisms involved in tumour rejection 
cannot be predicted from the use of the same cytokine in different tumour models. 
Nevertheless, such mechanisms underlying cytokine-induced tumour rejection in 
specific tumour models are important in that they allow an insight into the 
combination of cytokines that may produce complementary effector mechanisms and 
further enhance tumouricidal effects.
A combined cytokine experiment of this type was carried out by Ohira and co-workers 
(1994) in which IL-2 and TNF were co-transfected into the Lewis Lung carcinoma. It 
was reported that C57BL/6 mice rejected an innocculum of the cytokine secreting 
tumours, with the effects of the co-transfectants being superior to that of the IL-2 and 
TNF transfectants alone. This is in contrast to the human studies where systemic TNF 
has been unsuccessful in the clinical treatment of most cancers (Table 1, Kunkel et al
1992). Furthermore when TNF was transfected into MCA102 cells and injected into 
C57/BL6 mice, tumours grew progressively (Karp et al., 1993). Therefore, it would 
appear that the combination of TNF with another cytokine such as IL-2 may have 
superior efficacy compared with that of TNF alone.
It has also been reported that IL-2 secreted by renal cancer cells is capable of 
enhancing cytotoxic lymphocyte recognition of TILs isolated from autologous 
patients (Schendel and Gansbacher, 1993). TILs were isolated from a patient with 
renal cell carcinoma and an autologous LAK cell population was generated by 
culturing the peripheral blood lymphocytes with high doses of rIL-2. The recognition 
of IL-2 secreting tumour cells by TILs was enhanced in comparison to TIL 
recognition of unmodified tumour cells. However, LAK cell recognition of the IL-2
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secreting tumour cells appeared to be unchanged or slightly reduced (Schendal and 
Gansbacher, 1993). As discussed previously in section 2.6.2, TILs have proved more 
effective than LAK cells for the treatment of cancer in animal models. However in 
clinical trials, treatments using TILs have been disappointing whereas LAK-cell 
therapy appeared to be more effective. Perhaps the method as described by Schendal 
and Gansbacher (1993) could lead to an enhanced effectiveness of TILs in the clinical 
setting. Furthermore, Schendal and Gansbacher (1993) reported that the recognition of 
IL-2 secreting tumour cells by TILs appeared to be further enhanced when the tumour 
cells were pretreated with exogenous IFN-a. This effect was proposed to be due to an 
up-regulated expression of MHC class I molecules (Schendal and Gansbacher, 1993). 
In fact, cytotoxic lymphocytes appeared to be 50-150 fold more effective than LAK 
cells in lysing autologous tumour cell lines that had been transduced with both IL-2 
and IFN-a (Schendal and Gansbacher, 1993).
3.4 Gene Cell Therapy Using IFN-y
IFN-y has also been transfected into cell lines such as the renal cancer cell line, SK- 
RC-29 (Gastl et al., 1992). When injected into mice these IFN-y secreting cells 
formed large subcutaneous tumours. Microscopic examination of the tumour nodule 
showed that there was no cellular infiltration into these nodules, but the cells secreting 
IFN-y demonstrated increased expression of MHC class I antigen, 02 microglobulin, 
ICAM-1 and MHC class II antigen expression. A lot of importance has been placed 
on upregulated MHC expression by IFN-y as being important in the reduction of 
tumourigenicity. However, it has been demonstrated that modulated MHC expression 
is not the most important effector arm required for tumour cell destruction (Esumi et 
al., in 1991). When the spontaneous SP1 murine adenocarcinoma was transfected with 
IFN-y, the cells failed to grow when injected into syngeneic hosts and nude mice. It 
has been suggested that this lack of tumourigenicity was a result of MHC class I 
expression. However, more than 64units/ml of IFN-y was required to inhibit 
tumourigenicity whereas only 8units/ml were required to induce MHC class I
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antigens. Therefore, it would appear that some other effector mechanism must be 
involved in the anti-tumour response. Furthermore, IFN-y-secreting SP1 cells failed to 
protect against a challenge with parental cells, which may indicate that factors other 
than IFN-y production or class I MHC expression are needed to induce a protective 
response (Esumi et al., 1991). Therefore, it appears that an additional factor may be 
needed to prevent growth other than MHC. MHC class I has been proposed to be an 
important factor in the reduction of tumourigenicity and metastatic growth since the 
poorly immunogenic 3LL-D122 clone engineered to secrete IFN-y since IFN-y 
secretors showed significant decrease in tumourigenicity and metastatic growth, 
whereas non-secretors retain tumourigenicity and metastatic potential (Porgador et al., 
1993a). The IFN-y cells manifested high expression of MHC class I which was 
concluded to be a major participant in cytotoxic lymphocyte induction. Furthermore 
high levels of IFN-y secretion appeared to induce protective immunity in that a 
subsequent challenge of parental malignant cells was rejected (Porgador et al., 1993a). 
However support for the participation of non-T-cell-effectors in the response to IFN-y 
secretors derives from the reduced tumourigenicity of these cells in nude mice 
(Porgador et al., 1993a). Further support for non-MHC effector mechanisms of IFN-y 
were observed when the MBT-2 cells derived from a carcinogen-induced bladder 
tumour were infected with IFN-y (Saito et al., 1994). The cells secreting IFN-y grew 
slightly slower than the non-secreting cells when injected into mice. Histology in this 
case revealed that CD4+ as well as CD8+ T-cells were present at the site of secreting 
cells, but not unmodified cells. As well as the T-cells, macrophages were also found at 
the injection site. From this animal work it would appear that there are many possible 
effector mechanisms involved in tumour rejection.
3.5 Gene Cell Therapy Using IL-4
As previously discussed in section 3.1, macrophages (but not T-cells) were an 
important effector mechanism in the prevention of tumour cell growth when the 
J558L plasmacytoma and K485 adenocarcinoma cell lines were induced to secrete IL-
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4 (Tepper et al., 1989). Macrophages were also involved when murine renal cell 
tumours were engineered to secrete large doses of IL-4 but, in this case T-cells also 
appeared to be required for tumour rejection (Golumbek et al., 1991). When these IL- 
4 secreting renal cancer cells were injected into BALB/c mice they were completely 
rejected. Furthermore, tumour growth was not observed for 2 months when renal 
cancer cells secreting IL-4 cells were injected into nu/nu or SCID mice suggesting 
that T-cells were required for the ultimate rejection of tumour cells. Histological 
examination of the injection site revealed an influx of macrophages and some 
granulocytes. When CD8+ cells were eliminated from the animal the rejection of 
parental renal cancer cells at a distant site was prevented. Elimination of CD4+ T-cells 
had a lesser effect although there were some late recurrences suggesting that CD4+ T- 
cells participated in the long-term memory responses. Histological analysis of the 
rejecting challenge tumours revealed that CD3+ T-cells were a major component of 
the infiltrating population during the early stages of rejection (Golumbek et al., 1991). 
The importance of T-cells for IL-4 induced tumour rejection was again evident when 
J558L cells were induced to secrete IL-4 (Hock et al., 1993). Cell depletion 
experiments revealed that CD8+ T-cells were required for complete long-term tumour 
rejection, although effective, transient host-dependent tumour suppression was also 
observed in the complete absence of CD8+ T-cells. Again, immunohistochemical 
analysis revealed that a heavy infiltration of macrophages and some eosinophils was 
also required (Hock et al., 1993).
3.6 Gene Cell Therapy Using IL-7
IL-7 plays a major role in the proliferation of T and B-cells (Goodwin et al., 1988; 
Henney, 1989). When J558L cells expressing IL-7 were injected into mice they were 
completely rejected (Hock et al., 1991). However, this tumour rejection was not 
observed in nude mice, indicating the importance of T-cells. Immunohistological 
analysis of tumour tissue revealed an infiltration by CD4+ and CD8+ T lymphocytes, 
and also type 3 complement receptor positive cells (CR3+), which were
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predominantly macrophages. Depletion of T-cell subsets in tumour-bearing mice, 
initiated at the same time as the tumour injection, demonstrated the dependance of the 
anti-tumour response on CD4+ T-cells and CR3+cells , whereas tumour rejection was 
unaffected by depletion of CD8+ T-cells (Hock et al., 1991).
3.7 Gene Cell Therapy Using GM-CSF
The significance of T-cells in combination with other non-T-cell effectors was also 
observed when B16 melanoma cells expressing GM-CSF were injected into mice 
(Dranoff et al., 1993). It was reported that irradiated cells stimulated potent, long- 
lasting and specific anti-tumour immunity. The systemic immunity was long-lasting 
in that the majority of mice vaccinated with cells that express GM-CSF remained 
tumour free despite being subsequently challenged with non-transduced cells several 
months after vaccination. The systemic immunity was also specific in that GM-CSF 
expressing cells did not protect mice from a challenge of Lewis Lung carcinoma cells. 
When the vaccination site was examined an extensive influx of immature dividing 
monocytes, granulocytes and activated lymphoctes was observed. Depletion of CD4+ 
and CD8+ T-cells but, not NK cells prevented the reduced tumourigenicity. Similar 
results were reported when murine MBT-2 cells were also engineered to secrete GM- 
CSF (Saito et al., 1994). When injected into mice, GM-CSF cells grew more slowly 
than the controls and those that did not develop tumours were also resistant to a 
second tumour challenge. Histology revealed that CD4+ as well as CD8+ T-cells were 
again present at the injection site of cytokine-secreting cells, as were macrophages.
3.8 Gene Cell Therapy Using G-CSF
Neither T-cells, NK cells or macrophages were involved when C-26 murine colon 
carcinoma cells transduced with the human gene for G-CSF lost their tumourigenicity 
when injected into BALB/c mice (Colombo et al., 1992). Tumour rejection appeared 
to be mediated through a mechanism that involved increased numbers of neutrophils
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at the site of tumour rejection. Electron microscope analysis of the infiltrated tumours 
showed that the neutrophils appeared to be in intimate contact with the tumour cells.
3.9 Gene Cell Therapy Using IL-12
IL-12 was originally identified as NK cell stimulatory factor (Kobayashi et al., 1989). 
It is secreted by macrophages and some B-cell lines and it appears to induce NK cells 
and T-cells to produce IFN-y (Chan et al., 1992). In addition, IL-12 may also enhance 
NK activity and highly specific cytotoxic T-cell responses (Zeh et al., 1993). IL-12 
also appears to facilitate a Tfj-1 response but inhibits differentiation of Tjj-2 
lymphocytes (Manetti et al., 1993). The potential anti-tumour effects of IL-12 have 
also been studied experimentally. BL-6 cells (a poorly immunogenic murine 
melanoma cell line) were innoculated into C57BL/6 mice (Tahara et al., 1994). The 
tumour cells were admixed with NIHT3 cells which had been transfected with IL-12 
or the neomycin phosphotransferase gene. Compared to mice which were given 
injections of BL-6 cells admixed with non-secreting cells, the emergence of tumours 
was significantly delayed in mice given injections of BL-6 cells admixed with IL-12 
secreting cells. Histological examination of the tumour innoculum from high amounts 
of IL-12-secreting cells showed reduced tumour volume and necrosis in comparison 
to the control admixture. However, infiltration of the tumour by either macrophages or 
lymphocytes was not enhanced by IL-12 production, and high levels of IL-12 actually 
decreased the number of CD4+ T-cells infiltrating into the tumour (Tahara et al.,
1994). IL-12 secreted from fibroblasts also appeared to efficiently eliminate or 
suppress growth of an established MCA207 sarcoma when injected at the site of 
tumour growth (Zitvogel et al., 1995). It was reported that in less immunogenic 
tumours (MCA 102, MC38), established lung metastasis could be significantly 
reduced following delivery of IL-12 secreting fibroblasts and systemic administration 
of low doses of IL-2. Histological analysis of the regressing tumours revealed an 
infiltration of CD4+ and CD8+ T-cells plus macrophages. Another encouraging 
finding from these experiments was the lack of toxic side-effects. Tests of renal and
46
liver function monitored during the treatments were within the normal range. 
Therefore, it would suggest that IL-12-secreting fibroblasts could serve as an 
effective, non-toxic anti-tumour treatment (Zitvogel et al., 1995).
3.10 Gene Cell Therapy : Summary
So far, tumour cell targeted gene transfer has proved successful in anti-tumour activity 
and useful in analyzing the effector mechanisms involved in tumour destruction in 
vivo in animals. These experiments indicate that the immunological mechanisms by 
which tumours are rejected after cytokine gene cell transfer are varied not only by the 
cytokine, but also by the tumour model. This may be because tumour cells differ in 
the susceptibility for host effector mechanisms because of different surface molecule 
expression (e.g. MHC, adhesion molecules), soluble mediators other than the 
transfected cytokine gene, growth kinetics and immunogenicity. Other parameters 
such as the mouse strain or the level of cytokine expression may also influence the 
mode of rejection. Nevertheless, these studies point to which gene products or 
combinations thereof are best able to stimulate anti-tumour immunity in a variety of 
animal tumour models and gene transfer may prove to be a powerful tool for 
preventing tumourigenicity in humans
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3.11 The FS-29 Cell Line
The FS-29 cell line is a weakly immunogenic murine fibrosarcoma from which a 
panel of cell lines has been generated by infection with recombinant retroviruses to 
enable it to carry cytokine cDNAs initially for IL-2 and IL-4 (Patel et al., 1993a) and 
subsequently IFN-y (Patel et al., 1993b). In order to generate a control cell line, FS-29 
cells were infected with a retrovirus lacking any cDNA insert. This section details 
experiments carried out by Patel and co-workers to investigate the anti-tumour 
potential of this modified cell line (1993). Initial experiments were carried out to 
establish whether the growth rates of the cytokine secreting cells was different from 
the non-secreting cells. It was found that the in vitro growth rate of the cytokine- 
secreting clones was not different from the non-secreting clones. It was reported that 
the individual clones secreted varying levels of the same cytokine; therefore those 
clones secreting the highest amount of cytokine were chosen for the experiments.
When 1()6 FS-29 IL-2-secreting cells were injected into C57/BL6 mice, Patel and co­
workers reported that tumour nodules formed which then completely regressed in 
most animals. In the tumours which did arise from these clones, it was reported that 
the tumour cells secreted considerably reduced, or no IL-2, which was attributed to a 
decrease in the IL-2 encoding retroviral integrant. FS-29 IL-4 secreting clones also 
have demonstrated slower growth rates and reduced tumourigenicity when injected 
into C57BL/6 mice. However, when tumours from the IL-4 injected mice were 
explanted, their IL-4 secretion was found to be unreduced, and they appeared to have 
retained the retroviral integrant encoding IL-4. When IL-2 and IL-4 were doubly- 
transfected into the one cell line, this combination resulted in optimal tumour rejection 
suggesting that the two cytokines might mobilize different and complementary 
effector mechanisms.
When the explanted tumours were examined histologically and morphologically, the 
tumours formed from the unmodified FS-29 cells appeared to have few infiltrating
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host cells. Pronounced lymphocytic infiltrations were observed in the tumours which 
formed from the IL-2 secreting cells, the majority of which appeared to be CD8+ T- 
cells, with a few CD4+ T-cells and some B-cells. The tumours which formed from the 
IL-4 secreting cells were characterised by a macrophage and granulocyte infiltration, 
with a small number of CD8+ and CD4+ T-cells. Further studies indicate that neither 
IL-2, nor IL-4 secreting FS-29 cells resulted in any slowing of growth when injected 
into mice with an equal number of admixed non-secreting FS-29 cells. Furthermore, it 
was reported that tumours which formed from admixtures of IL-2 and parental cells 
excised at day 14, appeared to have lost their IL-2 secretion which correlated with a 
loss of IL-2-encoding retroviral DNA sequences. Similar analysis of admixtures of IL- 
4 secreting and parental cells demonstrated greatly reduced IL-4 secretion after 14 
days growth in vivo, and undetectable IL-4-encoding retroviral DNA. A more rapid 
loss of IL-2-secreting cells was reported in an admixture of IL-2 and IL-4 secreting 
cells with parental cells.
An alternative application of retroviral cytokine gene delivery in cancer therapy would 
be the use of tumour cells cultured following primary lesion excision and infected 
with cytokine encoding retroviruses. These cells could be administered as an injection 
to enhance eradication of minimal residual disease. Patel and co-workers reported that 
animals which had rejected the IL-4 secreting tumour cells showed considerably 
delayed tumour incidence when challenged after 48 days with FS-29 control cells. 
However, the IL-2 secreting tumour cells did not protect animals against a delayed 
parental cell challenge. This data suggests that IL-4 secreting tumour cells, while 
unable to induce a rapid enough immune response to cause the rejection of admixed 
parental cells, may stimulate an effective long-term anti-tumour response.
Subsequently, the cDNA for IFN-y has been inserted into the FS-29 cell line (Patel et 
al., 1993b). When these IFN-y secreting tumour cells were injected subcutaneously 
into C57/BL6 mice, the clones secreting IFN-y developed tumours, which in most
49
cases regressed. Furthermore, when 10^ FS-29 control cells, IL-2, IL-4 or IFN-y 
secreting cells were injected into nu/nu mice, only the IL-2 secreting cells were 
reported to have slowed tumour growth and subsequent regression. Since the other 
cytokine-secreting and non-secreting cells formed tumours, this indicates the 
importance of T-cells for the anti-tumour mechanisms of IL-4 and IFN-y. When non­
secreting cells were injected either alone or with IL-2, IL-4 or IFN-y secreting cells, 
growth of those injected with IL-2 or IL-4 admixtures appeared to be slightly slower 
than the controls, but the IFN-y admixtures demonstrated the most successful slowing 
of growth, with the mean tumour diameter being around half of the control tumour 
size.
From the above, it would appear that the FS-29 cell-line is to date one of the most 
characterised cell-lines and has been used successfully in a number of gene cell 
therapy studies in animals. This cell-line was therefore chosen to be used in studies of 
gene cell therapy described in this thesis.
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3.12 Aims
Based on the previous reports of the FS-29 cell line, the aims of the work were to 
further examine the effectiveness of this cell line by addressing the following 
questions;
1) When the animals are given a two-site injection of cells, is there a systemic 
reaction that prevents growth of the tumour cells and is this systemic 
protection dependant on the cytokine that the tumour cell secretes? 
Furthermore, is the ability to promote systemic protection dependant on the 
tumour burden?
2) Can those animals that have previously received secreting or non-secreting 
cells, which then grew slowly or did not grow at all, transfer immune memory 
to a naive animal and therefore protect against a subsequent tumour 
challenge? Is this protection again dependant on the original tumour burden?
3) Are the cytokine-secreting cell lines able to slow or regress growth of an 
already established tumour? Furthermore, are there any additive or 
antagonistic interactions of the cytokine secreting cells when administered in 
various combinations?
Furthermore, it proposed to examine the possible effector mechanisms involved in the 
anti-tumour responses of each of the cytokine-secreting cells for each of the above 
studies.
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4.METHODS: DNA ANALYSIS OF THE FS-29 CELL-LINE
4.1 Introduction
The FS-29 cells were a gift from Dr. M. Collins (Institute of Cancer Research, 
London, U.K.) and their previous use experimentally has been discussed in detail in 
section 3.11. In order to use these cell-lines for further animal experiments, they had 
to be cultured and passaged in the appropriate medium to produce adequate stocks 
that could be harvested for in vivo experiments. This process is detailed in section 4.2.
Before the cells could be used for animal experiments, it was important to check that 
there was no cross-contamination of the cell lines. Therefore, DNA analysis of each 
cell line was carried out to check that there was only one cytokine gene present in 
each cell line or, in the case of the control cells, that there was no cytokine DNA insert 
present. DNA was isolated from each of the cell lines and amplified using the 
technique of polymerase chain reaction (PCR). The products were then run on an 
agarose gel in order to detect the possible presence of the genes for the cytokines IL-2, 
IL-4 and IFN-y in each cell-line. The methods of DNA extraction and amplification 
are detailed in sections 4.3 and 4.4, and the results from these techniques are described 
in sections 4.5 and 4.6.
4.2 Culture of the FS-29 Cell Lines
The FS-29 cell lines were continually cultured and passaged throughout the duration 
of the animal experiments in Dulbecco's modified eagles medium (DMEM). This also 
contained penicillin-streptomycin (pen.TOO units/ml, strep:0.1 mg/ml), L-glutamine 
(2mM) and 10% v/v foetal calf serum (All from Biological Industries Ltd. 
Cumbernauld, U.K.). The cells were cultured in an incubator at 37°C with 5% CO2 
and harvested by firstly removing the culture medium and then washing in phosphate 
buffered saline (PBS, pH7.4). The cells were dissociated from the culture flask by the 
addition of 0.02% EDTA in PBS under incubation at 37°C for 15 minutes. In order to 
obtain a cell pellet, the cell suspension was centrifuged at 350g for 10 minutes (Jouan
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Ltd., Ilkeston., U.K.). The supernatant was decanted and the cells were washed in PBS 
for 10 minutes in a centrifuge at 350g.
When the cells were required for animal experiments they were counted using an 
"improved Neubauer" haemocytometer (Sigma Chemical Co. Dorset, U.K.) and the 
cell density was adjusted by the addition of PBS.
4.3 Isolation of Genomic DNA
A sample of each of the cell lines was harvested using the method described in section 
4.2. The cell pellet obtained was resuspended in 500pl of PBS and stored at -20°C 
until required. The previously-isolated cells were allowed to thaw and sodium acetate 
was added to give a final concentration of 0.3M in a final volume of 1ml and the 
solutions were mixed gently. 150jli1 of a 10% solution of sodium dodecyl sulphate 
(Sigma Chemical Company, Dorset U.K.) was added to burst open the cells. 150pl of 
a 1 mg/ml solution of proteinase-K (Stratagene, Cambridge, U.K.) and 200pl of sterile 
water were then added to digest the excess protein. The solutions were mixed gently 
and incubated at 37°C for 48 hours.
After incubation, the resultant viscous solution was split between 2 x 1.5ml 
microcentrifuge tubes and an equal volume of Tris/EDTA-saturated 
phenol:chloroform was added (pH8) to extract the protein. The tubes were vortexed 
briefly and the aqueous and solvent layers were separated by centrifugation at 
13,500rpm for 10 minutes in a microcentrifuge (Scotlab Ltd. Coatbridge, U.K.). The 
upper layer containing the genomic DNA was removed by pipetting and placed into a 
new microcentrifuge tube and an equal volume of Tris/EDTA saturated 
phenol:chloroform added. The tubes were vortexed briefly and the aqueous and 
solvent layers were separated by centrifugation in a microcentrifuge at 13,500rpm for 
lOmins. The upper layer containing the genomic DNA was removed by pipetting and 
placed into a new microcentrifuge tube and an equal volume of chloroform was
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added. The tubes were vortexed briefly and the aqueous and solvent layers were again 
separated by centrifugation as previously carried out. The upper layer containing the 
genomic DNA was removed by pipetting and placed into a new microcentrifuge tube 
and a 1/1 Oth volume of 5M ammonium acetate (pH 8) and 1ml of ice-cold ethanol 
were added to precipitate the DNA. Genomic DNA was removed from the mixture by 
spooling onto sealed glass pasteur pipettes and allowed to dry for 2-3 hours.The 
resultant DNA pellet was washed firstly in ethanol then sterile water and left to 
dissolve in fresh sterile water.
4.4 PCR of the DNA Samples
PCR of the DNA samples was carried out according to the method described by 
Sambrook and co-workers (1989). Primers for this experiment comprised; mouse IL-2 
which has an expected product size of 451 b.p., mouse IL-4 with an expected product 
size of 279 b.p., and mouse IFN-y which has an expected product size of 405 b.p 
(Stratagene, Cambridge, U.K.). The primers were reconstituted in lOOpl of 5mM tris, 
0. lm  EDTA to give a working stock of 25pM. For PCR the primers were used at a 
final concentration of lpM.
For each PCR reaction the following mix was prepared which was added to each 
reaction; 1 unit of Taq polymerase - (Advanced Biotechnologies, Surrey, U.K.), 5pl of 
10 x buffer (Advanced Biotechnologies, Surrey, U.K.), 5 j l l 1 of 10 x  dNTP's 
(Pharmacia Biotech. Ltd., St. Alban's, U.K.), 1.5mM magnesium chloride (Advanced 
Biotechnologies, Surrey, U.K.) and 2pl of target DNA. This mixture was made up to 
50pi using sterile water, and 2 drops of mineral oil were added to each tube to prevent 
evaporation of the solution.
The PCR reaction was carried out in a thermoblock (Biometra Ltd., Kent, U.K.) under 
the following conditions; 5 minute denaturation at 94°C, 5 minute annealing at 60°C,
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35 cycles of 1.5 minutes at 72°C, 45 seconds at 94°C, 45 seconds at 60°C, and a final 
extension of 10 minutes at 72°C.
Following PCR, lOjal of orange G (30% v/v solution of glycerol and 0.2mg/ml of 
orange G - Sigma Chemical Co., Dorset, U.K.) was added to give weight to each 
sample and lOpl of the final sample was added to each well. The samples were run 
along a mini-gel rig (Pharmacia Biotech. Ltd., St. Alban's, U.K.) 70mA for 1 hour on 
a 2% agarose gel with 1 x TAE buffer (0.04M tris acetate, 0.001M EDTA, pH 8).
IOjllI of ethidium bromide was added to stain the DNA. In this case the ladder used 
was cpX174 RFDNA/Hae III fragments which is suitable for sizing linear double­
stranded DNA from 72-1353 bp (Gibco BRL., Paisley, U.K.). The gel was developed 
using ethidium bromide and examined under UV light and photographed.
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4.5 Results
Table 4.1 and figure 4.1 demonstrate the results from the products of the PCR 
reactions. Gel 1, lane 1 contained the marker which was used to estimate the size of 
the DNA bands. Lane 2 contained DNA from untransduced parental FS-29 cells and 
the primer for IL-2, there was no band present in this lane. The primer for IL-2 and 
and the DNA extracted from the control cells was present in lane 3 which also 
remained blank. Lane 4 contained the DNA from the IL-2 secreting cells and the IL-2 
primer. There was a band present in this lane which corresponded to the size of the IL- 
2 insert. No bands were present in lane 5 which contained the IL-2 primer and the 
DNA extracted from the IL-4 cells or in lane 6 which contained the IL-2 primer and 
DNA from the IFN-y cells. Lanes 7 and 8 were also blank. Therefore it can be 
concluded that only the IL-2 cell-line contained the IL-2 insert.
Gel 1, lane 9 contained the IL-4 primer and untransduced control FS-29 cells. This 
lane remained blank as did lane 10 which contained the IL-4 primer and DNA 
extracted from the control FS-29 cells. Lane 11 contained the IL-4 primer and DNA 
extracted from the IL-2-secreting cells. This lane did not contain any bands. However, 
a band corresponding to the size of the IL-4 gene was present in gel 2, lane 2. This 
lane contained the IL-4 primer and DNA from the IL-4-secreting cells. No bands were 
present in gel 2, lane 3 which contained the IL-4 primer and DNA extracted from the 
IFN-y-secreting cells. Lane 4 only contained the primer and no DNA sample, and 
there was no band in this lane. Gel 2, lane 5 was blank. From these results it can be 
concluded that only the IL-4-secreting cells contained the gene for IL-4.
Gel 2 , lanes 6-11 contained the primer for IFN-y along with DNA extracted from 
each of the cell-lines. No band was present when the IFN-y primer was present with 
DNA extracted from the untransduced parental cells or the FS-29 control cells (lanes 6 
and 7). However, bands were present in gel 2 lanes 8 and 9 which contained the IFN-y 
primer but DNA extracted from the IL-2 and IL-4-secreting cells. The bands were
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close to the size of the IFN-y gene, so it would seem that these lanes may have been 
contaminated. Another band was present in gel 2, lane 10 which contained the IFN-y 
primer and DNA extracted from the IFN-y-secreting cells. This band corresponded to 
the size of the IFN-y gene. Lanes 11 only contained the IFN-y primer and no DNA 
sample, and there was no band in this lane. Lane 12 was blank and there was also no 
band in this lane. From these results it can be concluded that the IFN-y-secreting cell- 
line contained the gene for IFN-y.
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4.6 Discussion
Examination for the presence of the cytokine genes using DNA electrophoresis 
indicated that, none of the cell-lines were contaminated with the IL-2 and IL-4- 
secreting cells. However, there was evidence that both the IL-2 and IL-4 cell-lines 
appeared to be contaminated with DNA for IFN-y. From the results of the gel the non­
transfected cell-line did not appear to contain the genes for either IL-2, IL-4 or IFN-y. 
Furthermore, it is unlikely that DNA for IFN-y could be inserted in to the parental 
cells during their transfection with IL-2 and IL-4 (Viewig and Gilboa, 1995). 
Therefore, it would appear unlikely that the contaminated bands were due to IFN-y 
DNA from the IL-2 and IL-4-secreting cells. It may be that these bands were a result 
of spillage from the IFN-y cell lane.
Clearly, the fact that these cell-lines contain the gene for the relevant cytokine does 
not establish that these cells are actually secreting cytokines. In order to do this the 
presence of mRNA expression could be determined as an indicator of whether the 
cytokine DNA was being translated. This method was attempted in the lab, but was 
abandoned due to a number of technical difficulties and the lack of time available. In 
order to further establish that the cell-lines were secreting cytokines and to determine 
the level of the cytokine secretion it would be possible to use bioassays or ELISAs. 
However, these techniques were not available for use within this project. Furthermore 
there are problems associated with the use of bioassays (Chirmule et al., 1991) 
Therefore, it was assumed from the previous work carried out by Patel and co-workers 
(1993a, and personal communication from Dr. M. Collins) that the level of cytokine 
expression remained relatively constant for the cell-lines used in the present work. 
Indeed Patel and co-workers (1993a and personal communication) have defined the 
amounts of IL-2, IL-4 and IFN-y expressed by these cell lines as 
25000U/10^cells/48hrs, 74500U/10^cells/48hrs and 50U/10^cells/48hrs respectively. 
There was no cytokine secretion by the parental cell-line and the transfected cell-lines 
only secreted one type of cytokine (1993a and personal communication).
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Table 4.1
Gel 1 Gel 2
1 - Marker. Lane 1 - Marker.
2 - IL-2 + parental cells. 2 - IL-4 + IL-4 cells.
3 - IL-2 + control cells. 3 - IL-4 + IFN-y cells.
4 - IL-2 + IL-2 cells. 4 - IL-4 + blank.
5 - IL-2 + IL-4 cells. 5 - Blank.
6 - IL-2 + IFN-y cells. 6 - IFN-y + parental cells
7 - IL-2 + blank. 7 - IFN-y + control cells.
8 - Blank. 8 - IFN-y + IL-2 cells.
9 - IL-4 + parental cells. 9 - IFN-y + IL-4 cells.
10 - IL-4 + control cells. 1 0 - IFN-y + IFN-y cells.
11 - IL-4 + IL-2 cells. 11 - IFN-y + blank.
12 - Blank. 12 - Blank.
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5: METHODS: TMMIJNOHISTOLOOICAL ANALYSIS OF RXCTSRD TUMOURS
5.1 Introduction
An indication of the extent of an immune response to a tumour is the nature of the 
lymphocytic infiltration. Patel and co-workers (1993a) examined the nature of the 
cellular infiltration into the tumours that formed during their studies (discussed in 
section 3.11). The presence of a lymphocytic infiltration has implications for the 
possible effector mechanisms that may be involved in tumour rejection, since 
rejection in many tumour models appears to be dependant on a lymphocytic 
infiltration (discussed in section 2.3). The tumours excised from the animal studies in 
this present work were analysed in order to examine the composition of the T and B- 
cell infiltration between the treatment groups. Structural differences in the tumours 
due to differing cytokine expression was also examined by routine histological 
staining.
5.2 Preparation of Crvostat Sections
All reagents were from Sigma Chemical Co. (Dorset, U.K.) unless otherwise stated. 
Glass slides were treated to increase their adhesiveness to sections by coating them 
with 3-aminopropyl-triethoxy-silane. The coated slides were prepared by firstly 
washing in acetone for five minutes followed by another five minutes in a 2% 3- 
aminopropyl-triethoxy-silane in acetone. The slides were thoroughly washed in 
running water for 30 minutes and allowed to dry. The tumour samples were removed 
from their storage in liquid nitrogen and 5pM tumour sections were cut in a cryostat 
(Bright Instrument Company Ltd., Huntingdon, England.) at -20°C and thawed onto 
the coated slides. The tumour samples were returned to liquid nitrogen storage as soon 
as sections were cut to minimise the risk of tissue damage. The sections were air-dried 
for thirty minutes, before being wrapped in tin-foil and stored at -70°C until required. 
Prior to immunohistochemistry, the wrapped slides were brought to room temperature 
before opening to prevent condensation forming on the sections. The sections were 
circled with a water impermeable pen in order to contain the solutions used during
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immunohistochemical staining and prevent leakage across the slide (Dako Ltd., High 
Wycombe, U.K.).
5.3 Non-Specific Staining
Preliminary experiments were performed to examine the extent of non-specific 
binding in the tumour samples. Sections were processed without primary or secondary 
reagents and just with the chromogen diaminobenzidine (DAB). In this way the extent 
of endogenous peroxidase activity could be assessed. In a proportion of cases, 
endogenous peroxidase activity was present in single cells within the sections. This 
was considered to be present in a significant number of cases and was of sufficient 
intensity to make the distinction between specifically stained lymphocytes and cells 
with endogenous peroxidase activity difficult. The following methods, which have 
been established for particular tissues, were used in an attempt to suppress the activity 
in these tissues (Polak and Van Noorden, 1986).
a) 1% hydrogen peroxide in tris-buffered saline (TBS, 0.01M 
Tris(hydroxymethyl)methylamine, pH 7.6 with HCL, 0.14M Sodium Chloride) for 30 
minutes.
b) 10% hydrogen peroxide in TBS. for 10 minutes.
c) 0.1% phenylhydrazine in TBS. for 1 hour at 37°C.
d) 1% hydrogen peroxide in methanol for 30 minutes.
Unfortunately none of the methods was sufficiently successful, either having no effect 
or being too strong a treatment resulting in removal of the section from the slide. An 
alternative solution to this problem was devised by staining the endogenous 
peroxidase black at the beginning of the procedure. In this way, the black cells with 
endogenous peroxidase activity could readily be distinguished from the specific 
antibody labelled cells which were ultimately stained red. This was done using a 
nickel-DAB solution (0.025% diaminobenzidine, 0.07 % NiCl2-7H20, 0.01% H2O2 
in PBS (0.01M sodium phosphate, 0.14M sodium chloride, pH 7.6)). DAB forms a
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brown precipitate on contact with peroxidase when catalysed by hydrogen peroxide. 
However, in the presence of nickel ions, this reaction results in a black precipitate. 
This phenomenon was used to differentiate between the endogenous peroxidase and 
the positively stained cells. This protocol is a modification of a double 
immunohistochemical staining technique developed by Hsu and Soban (1982).
Further preliminary studies carried out suggested that the tumour sections may also 
contain endogenous biotin-like activity. This was distinct from the endogenous 
peroxidase and was apparent in sections incubated with the streptavidin conjugate 
alone in the absence of primary antibodies indicating a specific binding of the 
streptavidin to the tissues. Biotin is a vitamin and coenzyme present in many tissues, 
and it binds to avidin and streptavidin with high affinity. This can result as non­
specific staining when using a streptavidin-bound enzyme complex such as 
streptavidin horse-radish peroxidase (Wood and Wamke, 1981). This binding activity 
is quite pronounced when using cryostat sections, but can be overcome by adding 
avidin to block the endogenous biotin. As avidin is tetravalent for biotin, it is then 
necessary to block the unoccupied sites with free biotin which would otherwise be 
able to bind the biotinylated antibodies used in the immunohistochemical procedures.
Methods have been described for the blocking of endogenous biotin using purified 
avidin. However, purified avidin may be replaced by egg white which is a rich source 
of avidin. Therefore, before application of the primary antibodies the sections were 
incubated with a 50% solution of egg white in PBS (a rich source of avidin) for 60 
minutes followed by a solution of 0.02% free biotin included in the serum blocking 
solution (Reeves et al., 1994).
A serum blocking solution was employed to reduce any further non-specific binding. 
25% non-immune rabbit serum and 25% normal human serum with 10% of each
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serum type included in the primary antibodies and streptavidin peroxidase complex 
resulted in sections with low non-specific staining.
5.4 Primary Antibodies
The availability of monoclonal antibodies made it possible to stain for CD3+ T-cells 
and its subsets of CD4+ and CD8+ T-cells, and also for B-cells. All antibodies were 
supplied conjugated with biotin (Cambridge Bioscience, Cambridge, U.K.). The 
optimum concentration of primary antibodies (the highest dilution possible without 
reduction of the signal) were pre-determined.
a) Hamster anti-mouse CD3s (IgG) - It reacts with the 25kDe chain of the receptor- 
associated CD3 complex expressed on all T-cells. It was used at a concentration of 
0.01 mg/ml.
b) Rat anti-mouse CD4 (L3T4) (IgG2a) - It reacts with the CD4 (L3T4) antigen found 
on a subpopulation of T cells. It was used at a concentration of 0.02mg/ml.
c) Rat anti-mouse CD8a (Ly-2) (IgG2a). This antibody is specific for the a  chain of 
the CD8 differentiation antigen (Ly-2 or Lyt-2) found on most thymocytes and a 
subpopulation of mature T cells (T suppressor/cytotoxic cells). It was used at a 
concentration of 0.02mg/ml.
d) Rat anti-mouse CD45R/B220 (IgG2a). It reacts with pre-B lymphocytes and 
lytically-active subsets of lymphokine-activated killer cells expressing the 
B220/CD45 phenotype . It was used at a concentration of 0.02mg/ml.
e) Isotype matched control antibodies were used in place of these primary antibodies 
at similar concentrations as negative controls in parallel sections.
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5.5 Immunohistochemical Labelling of Sections
The sections were fixed in absolute acetone for 15 minutes and washed in PBS before 
the endogenous peroxidase activity was revealed with a 10 minute incubation in 
nickel-DAB (Section 5.3). After 3 x 5  minute washes in PBS, the endogenous biotin 
was suppressed as described in section 5.3. The serum blocking solution (containing 
free biotin) was applied for 10 minutes and this was aspirated from the sections and 
replaced with the primary or control antibody solutions (section 5.4). After a 60 
minute incubation, the excess antibody was rinsed from the slide followed by 3 x 5 
minute washes in PBS. The sections were then incubated with streptavidin 
horseradish peroxidase (Dako Ltd., High Wycome, U.K.) for 30 minutes followed by 
3 x 5  minute washes in PBS. The peroxidase signal was developed using 3-amino-9- 
ethyl carbazole (AEC) as the substrate. An AEC tablet (20mg) was dissolved in 2.5ml 
of dimethylformamide. To this was added 47.5ml of 50mM acetate buffer (pH5) and 
25pi of fresh 30% hydrogen peroxide. The slides were incubated in AEC for 5 
minutes then, washed in PBS. for 5 minutes, followed by washing in running tap 
water for 5 minutes. They were counterstained in Harris's haematoxylin (Sigma 
Chemical Co., Dorset, U.K.) and dehydrated in alcohol. As AEC is alcohol soluble, an 
aqueous mounting medium was used. This was carried out by baking the sections with 
a thin layer of Crystal Mount (Biogenesis Ltd., Poole, U.K.) at 56°C for 20 minutes. 
The sections were then mounted with a synthetic mounting medium (DPX, BDH, 
Glasgow, U.K.). Negative control parallel sections were processed for each specimen 
using control antibody in the place of the primary antibody (section 5.4). A positive 
control section of mouse spleen (known to contain large numbers of T and B-cells) 
was processed with each batch of samples in order to ensure that staining was 
consistant throughout the studies.
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5.6 Results and Discussion
A method was developed that allowed immunohistological analysis of the 
lymphocytic infiltration to be carried out on the tumours excised from each animal. 
Each tumour sample was stained for CD3+, CD4+, CD8+ T-cells and B-cells. The 
CD3+ T-cell staining was unsatisfactory since this antibody cross-reacted with the 
matrix tissue of the tumour resulting in large amounts of non-specific staining (Figure 
5.1). A number of attempts to remove this non-specific staining such as biotin 
removal, reduction in antibody concentration, and addition of blocking serum were 
unsuccessful. Nevertheless, the extent of the T-cell response could still be obtained 
through the CD4+ and CD8+ T-cell staining. Conditions were established such that 
staining using the CD4+ and CD8+ T-cell antibodies and also the B-cell antibody 
were easily visualised in positive cells therefore allowing the samples to be scored.
Many of the studies which have examined the lymhocytic infiltration into the tumour 
nodules following cytokine or cytokine gene therapy, have not used a scoring system 
to determine the extent of the lymphocytic infiltration, but have qualitatively 
determined whether a particular cell type has infiltrated the tumour nodule (Tepper et 
al., 1989; Golumbek et al., 1991; Hock et al., 1991; Gallagher and Zaloom, 1992; 
Gastl et al., 1992; Tahara et al., 1994). Further studies have denoted the presence of a 
lymphocytic infiltration as being a positive and the absence of any lymphocytic 
infiltration as being negative (Hock et al., 1993; Saito et al., 1994). Therefore, in order 
to give a better indication as to the extent of the lymphocytic infiltration into the 
tumours that formed during the course of the present studies; the sections were coded 
and scored blind using a semi-quantitative four-point scoring system. This is a 
modification of the five-point scoring method used by Patel and colleagues (1993a) 
and Karp and co-workers (1993). However, the scorer did not observe a firm 
distinction between the ++ and +++ points in Patel's scoring method therefore, the 
five-point method was reduced to a four-point scoring system in the present studies. 
The four-point scoring system, used to analyse the tumours that formed from the
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following studies, was defined as follows; tumours which had no positively stained 
cells were given a negative score (-) as demonstrated on figure 5.2. Sections that had a 
poor infiltration of positively stained cells were given a + score (Figure 5.3). Tumours 
that had a moderate infiltration of positive cells were assigned a ++ score (Figure 5.4). 
Those tumours that had a strong infiltration of positive cells were given a +++ score 
as demonstrated on figure 5.5. The reproducibility of immunohistochemistry scoring 
can be questioned because of its qualitative nature, and has been rarely addressed in 
immunohistochemistry studies. In the present work, the reproducibility of the scoring 
system was assessed by the blind scoring of 30 slides on two separate occasions at 
least six months apart. There was agreement in scoring in 76% of the slides and those 
slides that were discordant from the original score differed by only one point on the 
four-point scoring system. Furthermore, none of the slides that scored negative on the 
first occasion scored positive the second time they were scored, and similarly, none of 
the positively scored slides were scored negative on the second scoring occasion. The 
discordant scoring results may have been due in part to the positive staining fading 
with time. From the above, the scoring system used was considered to give a 
reproducible, semi-quantitative measure of the degree of lymphocytic infiltration.
The establishment of the above staining and scoring methods allowed the examination 
of the nature of the lymphocytic infdtration and morphology of the tumours in the 
following animal experiments (see chapters 6, 7, and 8).
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Table 5.1 - Description of figures 5.1 - 5.5.
Figure Tumour Type Stain Score
5.1 IL-4 Cells. CD3+ T-cells
-
5.2 105 IL-4 T-cells
-
5.3 105 IL-2 T-cells +
5.4 105 IL-2 T-cells ++
5.5 105 IL-2 T-cells +++
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Figure 5.1 - 5 p m  tu m ou r  section from an animal that had received IL-4-secreting FS-29 cells. This  
section has been stained for C D 3 +  T-cells  using A EC  (red) and countersta ined with Harris's 
haem atoxylin .  Staining using this antibody  was unsuccessful, as can be seen from the large a m o un ts  o f  
non-specific  staining. A ttem pts  to rem ove  the background  staining was unsuccessful. 
x lO  m agnifica tion .
Figure 5.2 - 5 p m  tu m o ur  section from an animal that received 10^ IL-2-secreting FS-29  cells. This 
section has been stained for T-cells using A EC  (red) as the substrate and Harris's haem atoxylin  as the 
countersta in .  N icke l-D A B  has stained the endogenous  peroxidase  black as indicated by the arrow. 
There  are no positive cells present in this section and it has therefore been given a negative score  (-). 
x lO  magnifica tion .
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Figure 5.3 - 5 p m  tu m ou r  section taken from an animal that received 10^ IL-2-secreting  FS-29 cells. 
This section has been stained for T-cells  using A EC (red) as the substrate and Harris 's haem atoxylin  as 
the countersta in .  N icke l-D A B  has been used to stain the peroxidase-posit ive  cells black. T here  is a 
poor  ce llu lar infil tration into this tu m ou r  sam ple and it has therefore been given a + score, 
x 10 magnifica tion .
«
Figure 5.4 - 5pm  tu m o u r  section taken from an animal that had  received 10^ lL -2-secre t ing  FS-29 
cells. This section has been stained for T-cells (red). There  is a  m odera te  cellular infil tration into this 
sam ple  and it has therefore been given a ++  score, x 10 magnification.
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Figure 5.5 - 5 p m  tu m o u r  section taken from an animal that received 10^ IL-2-secreting  FS-29 cells. 
This section has been stained for T-cells (red).  There is a s trong cellular infil tration into this tum o ur  
sam ple w hich  is therefore given a + ++  score. xlO magnification.
6: TUMOUR GROWTH AND SURVIVAL IN GENE CELL THERAPY
6.1 Introduction
Several authors have reported that tumour cells, which have been genetically altered 
to secrete cytokines, may prevent tumour growth in an number of animal models 
(Tepper et al., 1989, Gansbacher et al., 1990a, Russell et al., 1991, Hock et al.,1993). 
It has also been reported that tumour rejection at one site may induce systemic 
protection in that growth of a second tumour may be prevented (Dranoff et al., 1993, 
Saito et al., 1994). Furthermore, studies indicate that tumour cells altered to secrete 
cytokines may also reduce the number of metastases (Porgador et al., 1993a).
Most studies that have been conducted to examine the extent of systemic protection in 
animals involve firstly, innoculating the animal with tumour cells and secondly, 
administering a subsequent tumour challenge only if the original tumour cells were 
rejected. However, it may be that at the time the primary tumour has been detected, 
dissemination may have already taken place. Therefore, such protocols do not entirely 
mimic the natural process of cancer dissemination. In order to take this confounding 
factor into account, one approach is to give a two-site injection of parental or 
cytokine-secreting tumour cells which would better mimic the metastatic process. The 
extent of the systemic protection induced by the different cytokine-secreting FS-29 
cells could therefore be examined. Patel and co-workers (1993b) reported that neither 
the IL-2 or IL-4-secreting cells were capable of slowing growth of an equal number of 
admixed non-secreting FS-29 cells. However, when the IL-2 or IL-4-secreting cells 
were present in a tenfold excess, there was an initial delay in the growth of the 
unmodified cells, but rapidly growing tumours were eventually formed in all animals. 
When an equal number of parental cells were admixed with IFN-y-secreting cells, 
there appeared to be significant slowing of tumour growth. Furthermore, when the 
IFN-y secreting cells were present in a tenfold excess, tumour rejection appeared to be 
induced in two of the seven animals. This would indicate that the original tumour 
burden is important in determining the extent of the anti-tumour response.
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The aim of the present study was to examine the extent to which cytokine-secreting 
FS-29 cells were capable of inducing systemic protection and so reduce the metastatic 
process in mice. Furthermore, in the present study the animals received two different 
amounts of cytokine-secreting or control cells which would indicate the effect of 
tumour burden on the ability to evoke a systemic anti-tumour response. Histological 
examination of any tumour nodules formed during the present study was also carried 
out to give an indication as to the effector mechanisms that may implicated in a 
systemic anti-tumour response.
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6.2 Materials and Methods
Cells were cultured and harvested as described in section 4.2.The cell density was 
adjusted to give stocks of lO^/ml and 10^/ml in PBS. Thirty-one female 8-week old 
immunocompetent C57BL/6J mice (Harlan U.K.) were randomized into 8 treatment 
groups (7 groups of 4, 1 group of 3). Mice were given at least a two-day settling in 
time before going on procedure. Four of the treatment groups received 10^ FS-29 
cytokine-secreting or control cells and the other four groups received 10^ control or 
cytokine-secreting FS-29 cells as a lOOpl injection through a 26-gauge needle into 
both flanks (illustrated in figure 6.1).
Animals were checked daily and tumour growth was measured by palpation between 
the thumb and first finger. When tumours reached approximately 1cm in diameter, the 
animals were killed by neck dislocation. The excised tumours were frozen in liquid 
nitrogen immediately and stored in liquid nitrogen until required for histological 
analysis. Immunohistochemical analysis of the individual tumour sections was carried 
out as detailed in chapter 5. After 57 days the experiment was terminated and any 
surviving animals were examined by autopsy for signs of tumour growth.
Statistics: Data are presented as the median of the tumour diameter and where 
appropriate, comparisons of data from different groups were analysed using the 
Kruskall-Wallis test, which is a non-parametric equivalent of a one-way analysis of 
variance (Minitab Inc., Pasadena, CA, U.S.A.). When the Kruskall-Wallis test showed 
a significant overall difference between groups, the groups with cytokine-secreting 
tumours were compared with the control group on a pair-wise basis using the Mann- 
Whitney test. Significance was assessed at the 5 percent, level.
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6.3 Results
Tumour growth and survival: The animals injected with 10^ tumour cells 
demonstrated varying rates of tumour growth and survival (Table 6.1). Of the animals 
injected with 10^ control cells, 2 were killed on day 24 and the remaining two were 
still tumour-free at the end of the experiment on day 57. In comparison with the 
control cells, the animals with IL-2-secreting cells were killed on days 21, 24 and 29. 
None of these animals survived until the end of the experiment.
Of the four animals injected with the IL-4-secreting cells, one was killed after 37 
days, another 2 after 38 days, with one animal surviving until the end of the 
experiment at day 57. However, this surviving animal did have evidence of a tumour 
at autopsy. Of the four animals injected with IFN-y-secreting cells, one was killed on 
day 38 however, the remaining 3 animals survived until the end of the experiment. 
However, one of the remaining three animals did have a substantial tumour when 
examined at autopsy.
Tumour growth rates and survival for the animals that received 10^ tumour cells is 
documented in table 6.2. Of the four animals injected with 10^ control cells, all 
developed tumours and were killed on day 23. Of the animals injected with 10^ IL-2- 
secreting cells, two mice were killed on day 22, one on day 23 and the last on day 24.
Similarly the animals injected with 10^ IL-4-secreting were killed on days 24, 38, and 
the last 2 on day 41. In contrast, of the four animals injected with 10^ IFN-y-secreting 
cells, all survived until day 57 when the experiment was terminated. Two of these 
animals did however have some evidence of ascites. The remaining two appeared to 
be completely tumour-free.
Statistical analysis of the groups using the Kruskall-Wallis test indicated that there 
was no significant difference between the treatment groups for the number of days of
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survival for the animals that received a 10^ cell inoculum (p = 0.107). However the 
groups that received a 10^ cell inoculum showed a significant statistical difference 
between groups for the number of days of survival (p = 0.006). Further analysis 
comparing individual treatment groups with control for the animals that had received 
a 10^ cell inoculum was carried out using a Mann-Whitney U-test. Results showed a 
significant difference between the IL-4 group and control group (p = 0.026) and the 
IFN-y group and control group (p = 0.023). However, there was no significant 
difference between the IL-2 group and control (p = 0.757) for the number of days of 
survival.
Immunohistological analysis: This was carried out on the tumours excised from each 
animal (Table 6.3). Each sample was stained for CD4+and CD8+ T-cells and B-cells. 
The resultant sections were scored using a four-point system (see section 5.6)
The tumours excised from the 10^ control animals scored a strong CD4+ T-cell 
response, moderate CD8+ T-cell response and a poor B-cell response. The tumours 
from the 10^ control animals scored poor CD4+and CD8+ T-cell and B-cell responses 
(Figures 6.2, 6.4 and 6.6). Tumours from the animals that had received 10^ or 106 IL- 
2-secreting cells scored strong CD4+ and CD8+ T-cell responses with a poor B-cell 
response (Figures 6.3, 6.5 and 6.7).
Of the IL-4-secreting tumours 7 scored a moderate CD4+ T-cell response and one 
tumour sample scored a poor CD4+ T-cell response. The CD8+ T-cell and the B-cell 
responses were poor in one half of the tumours and negative in the other. Although the 
degree of infiltration was low, the tumour structure was also very poor. In comparison 
to the other cell-lines, where the tumour had a definite structure (Figure 6.8), there 
were large areas of tissue necrosis and some holes in the IL-4 tumours (Figure 6.9). It 
was also noted that these tumours contained large amounts of peroxidase-like activity, 
particularly around the periphery which was not observed in the other treatment
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groups (Figures 6.10 and 6.11). As mentioned previously, the peroxidase was stained 
black using nickel-DAB and could therefore be easily identified (Section 5.2). 
Peroxidase may be released from macrophages therefore, a large amount may be an 
indication of a macrophage infiltration.
The tumours that formed from the IFN-y-secreting cells were also stained. One sample 
scored a moderate response for CD4+ and CD8+ T-cells with a negative B-cell 
response. The second sample scored a poor CD4+ T-cell response and negative CD8+ 
T-cell and B-cell responses.
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6.4 Discussion
The aim of this study was to assess the growth rates and survival of cytokine-secreting 
tumour cells in vivo using a two-site injection technique which has not been 
previously reported. The small number of animals examined in this study limited the 
power of the statistical analysis of the results and therefore most of the observations of 
the present study are of a qualitative nature. Two of the animals that received 10^ 
control FS-29 cells failed to develop tumours, while the other two were killed at 24 
days. This divergance in results for the control group further limited the possibility of 
detecting differences associated with the cytokine-secreting cells in the 10^ cell 
injection group.
When 1()5 or 10^ IL-2-secreting FS-29 cells were injected into both flanks of 
C57/BL6 mice, tumour nodules developed in all animals, which did not regress. There 
did not appear to be any systemic effect from the two-site injection with there being 
similar numbers of tumours formed from the IL-2-secreting cells as from the non­
secreting control FS-29 cells. Survival time of these animals which received 10^ IL-2- 
secreting cells was poorer than the control cells with the 10^ injection size having 
shorter survival rates than the 10^ control cell injection. Therefore, from this study, it 
appeared that the IL-2-secreting cells did not have reduced tumourigenicity. This was 
unexpected since Patel and co-workers (1993a) reported that when 10^ IL-2-secreting 
FS-29 cells were injected into C57/BL6 mice, the initial tumour nodules which 
formed completely regressed in most animals. However Patel's study was only with 
one injection site and not with 2 sites as used in the present study. Therefore, it may 
be that the tumour load was too great for the animal to mount a significant enough 
anti-tumour response.
It is of interest that the IL-2 secreting cells in the present study afforded no protection 
from tumour growth since this is contrary to the results observed with many other IL- 
2-secreting cell-lines. For example, CMS-5 cells engineered to secrete IL-2 lost their
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tumourigenicity and a long-lasting protective response against a subsequent challenge 
with parental CMS-5 cells was induced (Gansbacher et al., 1990a). Decreased 
tumourigenicity with IL-2 transfectants has also been observed with a variety of other 
cell-lines (Russell et al., 1991, Cavallo et al., 1992, Gastl et al., 1992 and Saito et al., 
1994), which was usually accompanied by a characteristic T-cell infiltration. In 
general, these experiments were performed with weakly immunogenic tumours for 
which IL-2 markedly suppressed tumour growth in vivo in correlation with the 
increased amount of the secreted IL-2. For example, when IL-2 was retrovirally 
transduced into a highly malignant and poorly immunogenic 3LL-D122 cell clone, 
both high and low IL-2 producers showed an elimination of tumourigenicity in 
syngeneic immunocompetent mice. However, in the nude mice, only the high IL-2 
producers showed a reduced tumourigenicity in comparison with the parental 3LL- 
D122 cells (Porgador et al., 1993b). A correlation between the increased amount of 
IL-2 produced from transduced tumour cells and the capability of tumour rejection 
was further demonstrated in a spontaneous adenocarcinoma cell-line (TS/A; Cavallo 
et al., 1992). While clones that released low amounts of IL-2 grew in 60% of 
syngeneic mice, clones that released large amounts of IL-2 were promptly rejected. 
Therefore, it may be that the IL-2-secreting cell-line used in the present study did not 
secrete large enough amounts of IL-2 to reduce the tumourigenicity of the cell-line. 
Furthermore, Patel and co-workers (1993a) also reported that tumours which arose 
from the IL-2-secreting FS-29 cells secreted considerably reduced or no IL-2 which 
was attributed to a decrease in the IL-2 encoding retroviral integrant. Therefore, if the 
retroviral integrant for the IL-2-secreting cells is unstable, perhaps the retroviral 
integrant was lost from the IL-2-secreting cells in the present study, resulting in a lack 
of IL-2 secretion and as a consequence, any anti-tumour response.
When the tumours that formed from the IL-2-secreting FS-29 cells were examined 
histologically, a strong CD4+ and CD8+ T-cell infiltration with a poor B-cell 
infiltration was observed. This is in accordance with the results from Patel and co-
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workers (1993a) who reported that a pronounced lymphocytic infiltration was present 
within the tumours that formed from the IL-2-secreting cells the majority being CD8+ 
T-cells with some CD4+ T-cells and B-cells. There was a strong cellular infiltration 
into the tumours in the present study but, in the case of the two-site injection 
experiment performed, these effector mechanisms were not able to prevent growth of 
the tumours. However, it has been reported that effector cells other than T-cells are 
important in the rejection of IL-2-secreting tumour cells. Rat sarcoma cells which 
were transduced with the human IL-2 gene and secreted IL-2 following transfer, were 
reported to have reduced tumourigenicity and metastatic potential both in athymic and 
immunocompetent rats which would indicate that effector cells other than T-cells are 
important for rejection (Russell et al., 1992). Other studies have reported that IL-2 
producing tumour cells show infiltration with T and NK lymphocyte populations, as 
well as neutrophils and eosinophils (Cavallo et al., 1992, Karp et al., 1993).
The survival of the animals injected with 10^ IL-4-secreting cells into both flanks, 
was not significantly different from that of the control animals. However, the animals 
injected with 10^ IL-4 cells had significantly longer survival times in comparison to 
the control group suggesting a retardation of tumour growth. Despite the prolonged 
survival, more animals developed 2 tumours suggesting that there was no systemic 
anti-tumour effect of IL-4. Patel and co-workers (1993a) also reported that FS-29 IL- 
4-secreting clones showed slower growth rates and reduced tumourigenicity in 
comparison to the control cells. A possible explanation for the IL-4-secreting cells 
being more effective than the IL-2-secreting cells could lie in the stability of their 
respective retroviral integrants. Patel and colleagues (1993a) reported that when 
tumours from IL-4 injected mice were explanted, their IL-4 secretion was found to be 
unreduced and the cells had retained the retroviral integrant encoding IL-4. The IL-2 
integrant was lost more quickly from the IL-2-secreting cells than the IL-4 from the 
IL-4-secreting cells. This may explain why animals receiving IL-4-secreting FS-29 
cells had longer survival times than those that had received the IL-2-secreting cells.
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Histological analysis of tumours from IL-4 treated animals showed that lymphocytic 
infiltrations were not as strong as those seen in the IL-2 treated animals. Most of the 
IL-4 secreting tumours had a moderate CD4+ T-cell response. The CD8+ T-cell and 
the B-cell response was poor in one half of the tumours and negative in the other. This 
is in accordance with Patel and co-workers (1993a) who reported that tumours that 
formed from the IL-4-secreting cells contained a small number of CD8+ and CD4+ 
lymphocytes. Patel and co-workers (1993a) also reported that these tumours contained 
a characteristic macrophage and granulocyte infiltration. Although tumours from the 
present study were not stained for macrophages, it was found that there were large 
amounts of peroxidase-positive cells present, particularly around the periphery of the 
tumours. Peroxidase may be released from macrophages, and a large amount of 
peroxidase may be an indication of a heavy macrophage infiltration. In order to 
substantiate this, the tumours would have to be stained specifically for macrophages. 
This would be difficult as it was found to be impossible to remove this peroxidase, 
which would mask any positive staining. One alternative would be to have a 
pathologist examine the morphology of these cells to indicate the extent of the 
macrophage and granulocyte infiltration. Tepper and colleagues (1989) reported that a 
macrophage infiltration was present when IL-4-secreting J558L plasmacytoma cells 
were injected into nu/nu mice, thus indicating that macrophages and not T-cells were 
an important effector mechanism for preventing tumour growth. Golumbek and co­
workers (1991) reported that IL-4-secreting renal cancer cells were completely 
rejected in immunocompetent mice. However, tumour growth was observed after two 
months when the cells were injected into SCID mice, indicating that T-cells were 
required for the absolute rejection of tumour cells even though there was the 
characteristic influx of macrophages and granulocytes. Treatment of tumour-bearing 
immunocompetent mice with anti-CD8+ T-cell antibodies to eliminate CD8+ T-cells, 
prevented the rejection of parental renal cancer cells, and elimination of CD4+ T-cells 
had a much lesser effect, although there were some late recurrences suggesting that 
CD4+ T-cells participated in long-term memory responses. Hock and co-workers
77
(1993) also reported that CD8+ T-cells were required for complete long-term tumour 
rejection of IL-4-secreting J558L cells and that this was associated with a heavy 
infiltration of macrophages and some eosinophils.
In the present study, the tumours that formed in those animals that had received IL-4- 
secreting FS-29 cells had a very poor general structure. In comparison to the other 
cell-lines, which produced tumours with a definite structure, there were large areas of 
necrotic tissue and some holes in these IL-4-secreting tumours. This difference could 
be due to the fact that IL-4 induces different genes, such as lipase, in activated 
cytotoxic lymphocytes than IL-2 does and this difference appears to correlate with 
increased lytic function of the lymphocytes by IL-4 (Grusby et al., 1990). Therefore, 
although the IL-2-secreting cells encouraged an extensive infiltration of lymphocytes, 
their cytotoxic activity may not have been as powerful as that of the lymphocytes 
induced by IL-4-secreting cells. Other actions of IL-4 which may enable it to elicit an 
enhanced immune response include its ability to upregulate the expression of MHC 
class-II. IL-4 has been shown to induce macrophages to express MHC class-II (Stuart 
et al., 1988) and to activate them to kill tumour cells (Crawford et al., 1987). Loss of 
tumourigenicity of IL-4-secreting tumour cells has also been associated with a 
massive infiltration of activated macrophages and eosinophils (Tepper et al., 1989, 
Golumbek et al., 1991).
IL-4 has been reported to induce adhesion molecules such as VC AM on endothelial 
cells (Thornhill et al., 1991). Through the expression of these adhesion molecules, the 
endothelium becomes activated to allow binding and migration of inflammatory cells. 
For example, IL-4 has been shown to induce specifically the expression of the 
adhesion molecule VCAM-1 on endothelium (Thornhill et al., 1991). The cell surface 
ligand for this adhesion molecule is the leukocyte integrin VLA-4. VLA-4 is 
expressed on both T and B lymphocytes, monocytes and eosinophils (Walsh et al., 
1991). It has been reported that VCAM-1 activation of human endothelium in vitro
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promotes the adhesion of purified eosinophils (Schleimer et al., 1992). These findings 
suggest that an eosinophilic inflammatory infiltration induced by IL-4 may relate to 
the specific introduction of VCAM-1 on the endothelial surface. Furthermore, it has 
been reported that depletion of eosinophils using a cytotoxic antibody renders mice no 
longer able to kill IL-4-expressing tumour cells (Tepper et al., 1992). Therefore, in the 
present study eosinophils and macrophages may have been implicated in the in the 
anti-tumour response observed with the IL-4-secreting cell-line.
In the present study, when 10^ IFN-y secreting FS-29 cells were injected into either 
flank of C57/BL6 mice, three of the four animals survived until the end of the 
experiment, although one of these animals did have a tumour. All four of the mice 
injected with 10^ IFN-y secreting FS-29 cells survived until the end of the experiment 
although two had very slight ascites. The survival times of the animals injected with 
1 IFN-y secreting cells were significantly different from the controls and this cell- 
line appeared to have a more reduced tumourigenicity than the other two transfected 
cell-lines.
Similar results were reported when the weakly immunogenic IFN-y-secreting murine 
fibrosarcoma lost its tumourigencity and induced a persistent anti-tumour immunity in 
animals. The local IFN-y release caused a T-cell mediated immunity against the 
tumour in association with up-regulation of MHC class-I antigens (Gansbacher et al., 
1990b). Comparable effects were found in mouse neuroblastoma and highly 
metastatic Lewis lung carcinoma cells transduced with the IFN-y gene. These tumour 
cells had a strongly suppressed tumour growth when inoculated in animals and 
induced a specific anti-tumour activity (Watanabe et al., 1989).
Histological analysis of the tumours from the IFN-y secreting cells resulted in one 
sample scoring a moderate CD4+ T-cell and CD8+ T-cell response and a negative B- 
cell response. The second sample scored a poor CD4+ T-cell response and negative
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CD8+ T-cell and B-cell responses. Since there appeared not to be a strong 
lymphocytic infiltration into these tumours, perhaps there may have been other 
effector mechanisms responsible for the decreased tumourigenicity observed with this 
cell-line.
One of the mechanisms involved in altering tumour growth is believed to be differing 
MHC class-I and-II expression between parental cells and transfectants. It has been 
reported that the expression of MHC antigens can dramatically enhance the 
immunogenicity of tumour cells (Gastl et al., 1992). Patel and colleagues (1993b) 
reported that the IFN-y secreting cells expressed high levels of MHC class-I and-II 
molecules, and the supernatant from these cells could upregulate MHC expression on 
parental FS-29 cells. Porgador and co-workers (1993a) reported that 3LL-D122 cells 
secreting IFN-y showed decreased tumourigenicity and metastatic growth. These IFN- 
y cells appeared to have a high expression of MHC class-I, which was thought to be a 
major participant in the cytotoxic lymphocyte induction and anti-tumour response. 
However, Esumi and colleagues (1991) proposed that an enhanced MHC expression 
was not sufficient to produce an anti-tumour response. When SP1 cells secreting IFN- 
y failed to grow in syngeneic hosts and nude mice it was thought that this abrogated 
tumourigenicity was due to MHC class-I expression, but greater amounts of IFN-y 
were required to inhibit tumourigenicity than was needed to raise MHC class-I 
expression; therefore another effector mechanism may be involved. Expression of the 
IFN-y gene in poorly immunogenic tumour cells resulted in tumour suppression in 
euthymic but not athymic mice, suggesting a major role for T-cells in the IFN-y anti­
tumour response (Watanabe et al., 1989; Gansbacher et al., 1990b). When the bladder 
cancer cell-line MBT-2 was infected with murine IFN-y using a retroviral system, no 
growth inhibition was observed in vitro, but MHC class-I expression was increased. 
However, when the transfected cells were injected subcutaneously, specific anti­
tumour immunity was generated and was proposed to involve CD8+ T-cells (Hiura et 
al., 1994).
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The mechanism of the anti-tumour response induced by IFN-y may also be related to 
macrophage activation. Varesio and co-workers (1984) reported that potent activation 
of mouse macrophages was possible by recombinant IFN-y. One effect of IFN-y 
stimulation in macrophages is to increase the expression of both MHC class-I and 
class-II antigens (Wallach et al., 1982). In addition to MHC antigens, IFN-y up- 
regulates the expression of cell-surface receptor (FcR) for IgG and thus increases 
antibody-mediated cellular cytotoxicity by macrophages, neutrophils and eosinophils 
(Petroni et al., 1988). One of the main functions of IFN-y appears to be to prime 
macrophages to mount a respiratory burst i.e. rapid production of oxygen radicals and 
hydrogen peroxide (H2O2) and this contributes to their toxic activities towards 
bacteria and intracellular pathogens (Flesch and Kaufmann, 1987). IFN-y has also 
appears to potentiate the respiratory burst of neutrophils to different stimuli 
(Cassatella et al., 1988). Further implications for eosinophils in the anti-tumour 
effects of IFN-y was reported when high doses of IFN-y were incorporated into gelatin 
chondroitin microspheres. When the microspheres were mixed with irradiated tumour 
cells and injected subcutaneously, an inflammatory infiltration predominantly 
consisting of eosinophils was present at the injection site (Golumbek et al., 1993).
From this study it appears that the IL-4 and IFN-y-secreting, but not the IL-2- 
secreting, FS-29 cells can reduce tumourigenicity. The IFN-y-secreting cells were the 
most successful in reducing tumourigenicity; however from the histological data there 
is little evidence of the mechanism of this anti-tumour response. With respect to the 
IFN-y-secreting cells, an indication of the effector mechanisms involved could 
perhaps be observed if larger cell numbers were injected into animals such that more 
tumours were formed. In order to establish the efficacy of these regimes, further 
animal studies are required.
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Table 6.1: Tumour Growth In Gene Cell Therapy In Mice (lO^Cells)
Animal
No.
Control IL-2 IL-4 IFN-y
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
1 24 6.7x5.8 21 6.2x9.6 37 5.6x4.5 38 4.0x2.0
2 24 5.3x6.4 
7.8x6.2
24 5.6x4.4 38 6.8x6.4 
5.8x3.2
57 12.3x 
10.6
3 57 N.T. 29 10.2x5.7 38 7.9x4.3
4.6x4.3
57 N.T.
4 57 N.T. 57 1.6x62 57 N.T.
Median 40.5 24 38 57
Table 6.2: Tumour Growth In Gene Cell Therapy In Mice (lO^Cells)
Animal
No.
Control IL-2 IL-4 IFN-y
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
5 23 9.1x7.4 22 3.6x3.5 
17.8x9.9
24 4.5x3.5 
6.8x3.4
57 Ascitic
6 23 6.3x4.5 
6.7x5.3
22 6.8x6.8 
4.6x5.0
38 3.6x3.6
8.6x6.4
57 Ascitic
7 23 6.7x5.4 
8.5x5.5
23 5.6x4.5 
6.3x4.5 
5.7x4.6
41 9.4x8.5 
21.4x4.3
57 N.T.
8 23 10.1x7.8 24 10.1x6.6 41 7.3x5.8 
5.7x3.7 
5.9x5.2
57 N.T.
Median 23 22.5 39.5 57
N.T. = No Tumour.
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Table 6.3 - Histological Analysis
Treatment CD4 CD8 B220
1(P Control +++ ++ +
1(P Control +++ ++ +
1(P Control N.T. N.T. N.T.
10^ Control N.T. N.T. N.T.
1(P IL-2 +++ ++ +
1(P IL-2 +++ +++ -
1(P IL-2 +++ +++ +
1(P IL-4 ++ + -
1(P IL-4 ++ - +
1(P IL-4 ++ - -
1(P IL-4 ++ - -
1(P IFN-y ++ ++ -
1(P IFN-y + - -
1(P IFN-y N.T. N.T. N.T.
1(P IFN-y N.T. N.T. N.T.
10° Control + - +
10^ Control ++ + +
10^ Control + + -
10^ Control + + -
10° IL-2 +++ +++ +
10° IL-2 +++ +++ +
10° IL-2 + +++ ++
10G IL-2 ++ +++ +
10° IL-4 ++ + +
10° IL-4 ++ + +
10° IL-4 ++ + -
10° IL-4 + + +
10° IFN-y N.T. N.T. N.T.
10° IFN-y N.T. N.T. N.T.
10° IFN-y N.T. N.T. N.T.
10° IFN-y N.T. N.T. N.T.
+ Poor Response. ++ Moderate Response.
+++ Strong Response. - No Response. 
N.T. - No Tumour.
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Table 6.4 - Description of Figures 6.2 - 6.11.
Figure Tumour Type Stain Score
6.2 10^ Control CD4+ T-cells +
6.3 105 IL-2 CD4+ T-cells +++
6.4 10^ Control CD8+ T-cells +
6.5 105 IL-2 CD8+ T-cells +++
6.6 10^ Control B-Cells +
6.7 105 IL-2 B-Cells +
6.8 10^ Control
Haematoxylin + 
Eosin
Well-defined 
tumour structure.
6.9 106 IL-4
Haematoxylin + 
Eosin
Poor tumour 
structure.
6.10 105 Control Nickel-DAB
Few peroxidase- 
positive cells.
6.11 105 IL-4 Nickel-DAB
Many peroxidase- 
positive cells.
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FIGURE 6.1
The mouse - subcutaneous injection into the flank
Figure  6.2 - 5 u m  section o f  tum o ur  taken from an animal that had received 10° control cells into either 
flank. The section has been stained for C D 4 +  cells using A E C  as the substrate (red) and countersta ined 
with Harris 's haem atoxylin .  There  is a  poor  (+) C D 4+  infil tration into this tum our. x lO m agnif ica tion .
Figure 6.3 - 5 p m  section o f  tum o ur  taken from an animal that had received 10^ lL-2 -secre t ing  cells 
into either flank. This section has also been stained for C D 4 +  cells using A EC  as the substrate  (red) 
and Harris 's haem atoxylin  as the counterstain . There is a s trong (+++) C D 4+  infiltration into this 
tum our  sample. xlO magnification.
Figu re  6A - I u m o u r  section taken from an animal that had received 1 ( P  contro l cells into e ither flank. 
This  5 p m  section w as stained for C D 8 +  T-cells using A EC as the substrate (red) and Harris's 
haem atoxy lin  as the counterstain. There  is a poor (+) C D 8+  infil tration into this tum our. 
x lO  m agnifica tion .
F igure 6.5 - 5 p m  tum our  section from an animal that had received 10^ lL-2-secre t ing  FS-29 cells. 
There  is a s t rong  (+++) C D 8+  infil tration into this tumour. x lO  magnification.
Figure 6.6 - This  tu m ou r  w as excised from an animal that had received 10^ control cells into either 
flank. The 5 p m  section has been stained for B-cells. The  pho tograph  show s a poor (+) B-cell 
infiltration into this tum our nodule. x lO  magnification.
Figure 6.7 - 5 p m  section from a tum our  excised from an animal that had received 10^ IL-2 secreting- 
cells into e ither flank. This photograph  is indicative o f  all the treatments, in that p oor  (+) B-cell 
infiltrations w ere  observed with all FS-29 cell types. xlO magnification..
Figure  - j-i'aematoxylm and eo's!n stain o f  a 5 p m  section o f  tu m o u r  taken from an an im al tha t 
rece ived  FS-29 control cells. The photograph  show s the well defined structure o f  the tu m ou r  sample, 
x 10 m agnif ica tion .
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Figure 6.9 - H aem atoxylin  and eosin stain o f  a 5pm  section o f  tum our  taken from an animal that 
rece ived  IL-4-secre t ing  FS-29 cells. In com parison to the above well defined structure  o f  the control, 
the s tructure  o f  this tu m ou r  section is poor, with with there being  som e necrosed areas and holes 
p resen t ( indica ted  by the arrows). x lO  magnification.
Figure  6 .10 - 5 p m  section o f  tum our  taken from an animal that had received 10-^  control cells into 
e ither  flank. T he  section has been stained with a control an tibody  and N icke l-D A B  w hich stains 
pe rox idase  positive cells. The  section has again been countersta ined with Harris's haem atoxylin .  This 
pho tograph  show s little peroxidase-posit ive cells which indicates a poor m acrophage  infil tration. 
x lO  magnification .
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Figure 6.1 1 - 5 p m  section from a tum our  taken from an animal that had received K F  IL-4-secreting  
FS-29 cells into either flank. This photograph show s a heavy  infil trate o f  perox idase-posit ive  cells into 
the tum our. This indicates that IL-4 m ay  induce a strong m acrophage  infiltration into the tum our, 
x 10 magnifica tion .
7: SPLENOCYTF, TRANSFER IN GRNR CELL THERAPY
7.1 Introduction
It has been reported that when animals have rejected cytokine-secreting cells, they 
may subsequently reject a challenge of control cells (Gansbacher et al., 1990a, 
Dranoff et al., 1993). This process indicates that the host immune system appears to 
have developed memory for the tumour cells. One such model of this type of immune 
recognition has been reported by Gansbacher and co-workers (1990a). In this study 
CMS-5 cells modified to secrete IL-2, demonstrated decreased tumourigenicity and 
protection against a subsequent challenge with CMS-5 non-secreting cells. 
Furthermore, this protective response appeared to correlate with tumour specific 
cytotoxic T-cells in the spleen of the treated animals.
The aim of this study was to attempt to transfer immune memory against tumour cells 
by transferring splenocytes from animals, that had previously received a tumour 
challenge and had survived, into naive hosts. The naive host would then be challenged 
with control cells, and the ability to reject this tumour would be assessed. Animals 
that survived from the first study had their spleens removed and their splenocytes 
harvested for use in this present study.
Histological examination of any tumour nodules that formed during the present study 
was also carried out to give an indication as to the effector mechanisms that may be 
implicated in the anti-tumour response.
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7.2 Materials and Methods
When the first study was terminated after 57 days, some animals had survived until 
this point with tumours that had not yet reached 1cm in diameter, or which had no 
tumour growth. These remaining mice were killed and their spleens excised and their 
splenocytes used in the present study. The spleens were teased open with forceps and 
the splenocytes were harvested into PBS and counted as described in section 5.2.
Thirty-four female immunocompetent C57/BL6J mice were randomised into seven 
groups (6 groups of 5, 1 group of 4). Each animal received 1x10? splenocytes intra- 
peritoneally through a 26 gauge needle. Each group received splenocytes from the 
following animals;
Group 1 received splenocytes from a naive mouse i.e. a mouse that had not previously 
received any form of treatment. Group 2 received splenocytes from a mouse which 
had previously received 10^ control FS-29 cells and did not develop a tumour. Group 
3 was injected with splenocytes from a mouse that had previously received 10^ IL-4- 
secreting FS-29 cells and had developed a tumour. Group 4 contained mice which 
received splenocytes from a mouse that had previously been injected with 10^ IFN-y- 
secreting FS-29 cells and had developed a tumour. Group 5 received splenocytes from 
a mouse that had previously been injected with 10^ IFN-y-secreting FS-29 cells and 
did not develop a tumour. Group 6 received splenocytes from an animal that was 
previously injected with 10^ IFN-y-secreting FS-29 cells and did develop a tumour. 
Group 7 received splenocytes from an animal that previously received 10^ IFN-y- 
secreting FS-29 cells and did not develop a tumour.
FS-29 non-secreting cells were cultured and harvested as described in section 5.2.
Two days after injection of splenocytes all mice received 10^ control FS-29 cells 
subcutaneously into the left flank through a 26 gauge needle. Animals were checked 
daily and tumour growth was monitored by palpation between the thumb and first 
finger. When tumour growth reached 1cm in diameter, animals were killed by neck
86
dislocation. The excised tumours were placed into liquid nitrogen immediately and 
stored until required for histological analysis. Immunohistochemical analysis of the 
individual tumour sections was carried out as detailed in chapter 5. After 56 days the 
experiment was terminated and any surviving animals were examined by autopsy for 
tumour growth.
Statistics: Data are presented as the median and where appropriate, comparisons of 
data from different groups were analysed using the Kruskall-Wallis test which is a 
non-parametric equivalent of analysis of variance (Minitab Inc., Pasadena, CA, 
U.S.A.).
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7.3 Results
Splenocyte transfer: The results from the splenocyte transfer study are shown in tables
7.1 and 7.2. The first treatment group contained 5 naive animals, in that they received 
splenocytes from mice that had not received any gene cell therapy. Following 
injection of control cells, three of the animals were killed on days 33, 40 and 47. The 
remaining two animals survived until day 56; however one of these animals did have a 
tumour.
The mice in group 2 received splenocytes from animals that had previously received 
105 control cells. Following challenge with the parental tumour cell-line, the animals 
were killed on days 27, 30, 35 and 42. None of the members of this group survived 
until the end of the experiment. Group 3 received splenocytes from mice that had 
previously received 10^ IL-4-secreting cells and had not developed a tumour. 
Subsequent challenge with 10^ non-secreting cells resulted in survival times of 31,
31, and 34 days and the remaining two animals survived until the end of the 
experiment on day 56. One of the surviving animals had developed a tumour, but the 
other appeared to be tumour-free.
Administration of splenocytes from animals who had previously received 10^ IFN-y 
cells and had developed a tumour, resulted in survival rates of 27, 35, 35 and 52 days 
in group 4. Group 5 contained animals that received splenocytes from mice that had 
been injected with 10^ IFN-y-secreting cells animals and did not develop tumours. 
Following tumour challenge, all of the animals survived until the end of the 
experiment. Three of the animals appeared to be completely tumour free, but one 
animal had a small tumour.
Group 6 received splenocytes from mice that were previously injected with 10^ IFN-y 
-secreting cells and had not developed tumours. All of the animals in this group did 
develop tumours when challenged with non-secreting cells and none survived until the
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end of the experiment. The animals were killed on days 18, 38, 38, 40 and 55. Group 
7 contained animals that received 1 Qp splenocytes from mice that had previously 
received 10^ IFN-y-secreting cells and had not developed tumours. When animals in 
this group were challenged with control cells, one animal was tumour free after 56 
days, but the remainder of the group all developed tumours and were killed on days 
27, 35, 39 and 40.
Statistical analysis of these groups using the Kruskall-Wallis test showed that there 
was no significant differences between the treatment groups for the number of days of 
survival (p = 0.113).
Histological Analysis: The histology results are detailed in table 7.3. The first 
treatment group, which had received naive splenocytes, scored a strong CD4+ T-cell 
response (Figure 7.1), a moderate CD8+ T-cell (Figure 7.3) and a poor B-cell 
response. Similar responses were also observed with animals injected with 
splenocytes from mice that has received 10^ control cells and did not develop a 
tumour. These samples also scored a strong CD4+ T-cell response, moderate CD8+ 
response and a poor B-cell response.
Group 3 contained animals that received splenocytes from mice that had previously 
been injected with 10^ IL-4-secreting cells and had developed a tumour and group 4 
contained animals that received splenocytes from an animal that was injected with 10^ 
IFN-y-secreting cells and also developed a tumour. Both of these groups scored a 
strong CD4+ T-cell response, a moderate CD8+ T-cell response and a poor B-cell 
response.
In group 5 there was only one animal that developed a tumour. This animal received 
splenocytes from a mouse that was previously injected with 10^ IFN-y-secreting cells 
and had not developed a tumour. This tumour sample scored a moderate CD4+ T-cell
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response, (Figure 7.2) a poor CD8+ T-cell response (Figure 7.4) and a poor B-cell 
response.
The two remaining groups received splenocytes from animals that had previously 
been injected with 10^ IFN-y-secreting cells. Both of these groups scored a moderate 
CD4+ and CD8+ T-cell responses and a poor B-cell response.
There appeared to be little or no peroxidase activity present in tumours that formed 
from any of the treatment groups. Tumours that formed in each of the treatment 
groups had necrotic areas, but the extent of tumour necrosis appeared to be more 
striking in tumours that formed from animals that had received splenocytes from mice 
previously treated with 10^ or 10^ IFN-y-secreting cells. The majority of these 
tumours had large necrotic areas and a poor general structure in comparison with the 
tumours that formed in mice that received splenocytes from a naive mouse (Figures 
7.5 + 7.6).
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7.4 Discussion
This study was carried out to assess the ability of anti-tumour immunological memory 
to be transferred between animals through the transfer of splenocytes. It was proposed 
that if animals have previously received tumour cells and survived, the animals may 
have antigen-specific cells in their spleens. Furthermore, if splenocytes from these 
animals were transferred to naive animals, it was proposed that protection against 
tumour growth may also be transferred in that a challenge with control tumour cells 
may be rejected.
In this study mice received 1 Qp splenocytes intra-peritoneally and two days later were 
challenged with 10^ control FS-29 cells. The first treatment group received 
splenocytes from a naive mouse followed by control FS-29 cells. In comparison with 
the survival rates from the first study when the animals received 10^ control FS-29 
cells, the survival rates from the present study were increased, perhaps indicating that 
in general, increased numbers of lymphocytes may enhance the immune response and 
perhaps help reduce tumourigenicity. In the second treatment group animals received 
splenocytes from an animal that had previously received 10^ control FS-29 cells and 
had not developed a tumour. Following challenge with parental cells all animals 
developed tumours and none survived until the end of the experiment which may 
indicate that there was little if any transfer of immunological anti-tumour memory in 
this group.
The third group received splenocytes from an animal that had previously received 10^ 
IL-4-secreting cells and had not developed a tumour. When animals in this group were 
challenged with control cells, two of the four animals survived until the end of the 
experiment, with one animal appearing to be completely tumour-free when examined 
at autopsy. Although none of the treatment groups demonstrated statistically 
significant differences, and given the small numbers of animals in the experiment, it 
would be of interest to compare the groups with greater animal numbers. Perhaps in
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this group, there may have been a slight transfer of protection against tumour growth, 
in that one of the treated animals did not develop a tumour. Histological analysis of 
the tumours that formed in this treatment group revealed that there was a strong CD4+ 
T-cell infiltration, a moderate CD8+ T-cell infiltration and a poor B-cell response. 
Previous studies have indicated that T-cells are important for a long-term anti-tumour 
response against IL-4-secreting cells. For example, when renal cancer cells were 
altered to secrete IL-4 and injected into nu/nu mice, tumour growth was not observed 
for 2 months which suggested that T-cells were required for the ultimate rejection of 
tumour cells. Furthermore, when CD8+ T-cells were eliminated from the animal, the 
rejection of parental renal cancer cells at a distant site was prevented. When CD4+ 
cells were eliminated, there were some late recurrences which suggests that CD4+ 
cells participated in the long-term memory responses (Golumbek et al., 1991). 
Golumbek and co-workers (1991) reported that macrophages may also be involved in 
the anti-tumour response. However, there was little or no peroxidase staining in the 
present tumour samples which would suggest that there was little macrophage 
infiltration into the tumour nodules.
Group 4 contained animals that had received splenocytes from an animal that was 
inoculated with 10^ IFN-y-secreting cells and had developed a tumour. Following 
challenge with 10^ control FS-29 cells, three animals developed tumours and none 
survived until the end of the experiment. One animal in this group was killed on day 
35 because it was thought to be ascitic. However, examination at autopsy failed to 
reveal any indication of tumour growth therefore, this animal may have remained 
tumour-free until the end of the experiment. There did not appear to be any transfer of 
anti-tumour memory in this group through the transfer of splenocytes. Similar results 
were observed with group 6 animals. Mice in this group received splenocytes from an 
animal that had previously received 10^ IFN-y-secreting cells and had developed a 
tumour. Following a challenge with parental cells all animals in this group developed
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tumours which indicated that there was little transfer of anti-tumour memory between 
these animals.
Animals in Group 5 received splenocytes from mice that had previously received 10^ 
IFN-y-secreting cells and had not developed a tumour. Only one animal in this group 
developed a small tumour and all animals survived until the end of the experiment. 
Perhaps if this group had contained more animals or the experiment was allowed to 
run for longer, more information about the mechanisms of tumour rejection would 
have been obtained. However, the result of this study is encouraging as it may indicate 
that protection against tuumour growth may be transferred between animals in this 
group. Group 7 contained animals that received splenocytes from a mouse that had 
been injected with 10^ IFN-y-secreting cells and had not developed a tumour. 
Following a challenge with control FS-29 cells, four of the five animals in this group 
developed tumours. Therefore, there appears to be little transfer of immunological 
anti-tumour memory between these animals. As the group that received splenocytes 
from an animal that was inoculated with 10^ IFN-y-secreting cells contained more 
surviving animals than the group inoculated with splenocytes from an animal that 
received 10^ IFN-y-secreting cells, it may be proposed that the initial tumour burden 
is important in determining the effectiveness of transfer of immunological anti-tumour 
memory.
Results from this study are encouraging and it may be possible to transfer protection 
from tumour growth between animals. Several authors have reported that when 
animals have rejected an initial injection of cytokine-secreting cells, the animals may 
subsequently reject an inoculum of non-secreting control cells either at the same site 
or at a different site (Gansbacher et al., 1990a; Dranoff et al., 1993). Therefore, these 
animals appear to have developed immunologic anti-tumour memory for the tumour 
cells. Gansbacher and colleagues (1990a) reported that when CMS-5 cells were 
altered to secrete IL-2, these cells demonstrated decreased tumourigenicity and
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subsequent protection against a challenge with CMS-5 non-secreting control cells. 
Furthermore, it appeared that this protective response correlated with tumour-specific 
cytotoxic T-cells in the spleen.
Histological analysis of the tumour nodules that formed in this study was carried out 
in order to assess the possible effector mechanisms that may be involved in the anti­
tumour response. It was found that all tumours that formed in animals that had 
received splenocytes from animals that had previously been injected with the IFN-y- 
secreting FS-29 cells appeared to have large necrosing areas and a poor general 
structure. Therefore, tumours that formed in these groups may have undergone a 
vigorous immunological anti-tumour response and may be dying tumours. Further 
histological analysis revealed that tumours that formed in animals that received 
splenocytes from mice that had previously been injected with 1 O^-IFN-y-secreting FS- 
29 cells and did develop a tumour, had a strong CD4+ T-cell response, moderate 
CD8+ T-cell response and a poor B-cell response. The groups that received 
splenocytes from animals that were previously treated with 10^ IFN-y-secreting cells 
had a moderate CD4+ and CD8+ T-cell response and a poor B-cell response. As there 
was only one tumour that formed in the group that received splenocytes from an 
animal that was inoculated with 10^ IFN-y-secreting cells and did not develop a 
tumour, a firm indication of the IFN-y anti-tumour response cannot be concluded. 
However, results from histological analysis indicate that CD4+ T-cells may be 
important with there being a moderate infiltration of this cell type into the tumour 
nodule. There appeared to be little involvment of CD8+ T-cells or B-cells in the anti­
tumour response as there was a poor infiltration of these lymphocytic groups into the 
tumour nodule.
It is an exciting possibility that protection against tumour growth may be transferred 
between animals through the transfer of lymphocytic cells. Unfortunately numbers
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were small in the treatment groups, but the approach used in this study warrants 
further investigation.
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Table 7.1: Splenocyte Transfer In Gene Cell Therapy
Animal
No.
Naive l(PControI
N.T
10s IL-4 
W.T.
1<P IFN-y 
W.T.
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
1 33 8.9x5.1 
ascitic
N.T.R.D 31 12.9x8.6
ascitic
27 10.0x7.6
2 40 11.6x8.5 27 12.6x9.8 31 9.7x12.9 35 9.4x7.0
3 47 8.4x10.9 30 5.3x4.4 
10.3x8.6
34 ascitic 35 N.T.
4 56 N.T. 35 10.1x8.5 56 N.T. 52 ascitic
5 56 7.5x6.9 42 8.5x8.5 56 9.5x6.6
Median 47 32.5 34 35
Table 7.2: Splenocyte Transfer In Gene Cell Therapy
Animal
No.
10s IFN-y 
N.T.
10b IFN-y 
W.T.
0
z 
£ 1
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
1 N.T.R.D 18 7.5x6.1 27 13.7x
12.2
2 56 4.1x6.6 38 10.7x7.6 35 10.3x
10.9
3 56 N.T. 38 ascitic 39 ascitic
4 56 N.T. 40 6.1x6.0* 40 ascitic
5 56 N.T. 56 12.6x
10.5
56 N.T.
Median 56 38 39
N.T.- No Tumour. W.T.- With Tumour.
N.T.R.D. - Non-tumour related death. * Ulcerated Tumour.
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Table 7.3 - Histological Analysis
Treatment CD4 CD8 B220
Naive ++ ++ +
Naive +++ ++ +
Naive +++ ++ +
Naive N.T. N.T. N.T.
Naive +++ ++ +
1(P Control N.T. ++ ++ -
1(P Control N.T. ++ + +
1(P Control N.T. +++ ++ +
1(P Control N.T. +++ ++ +
1(P Control N.T. +++ ++ +
1(P 1L-4 W.T. +++ ++ +
1(P IL-4 W.T. ++ ++ +
1(P IL-4 W.T. +++ ++ +
1(P IL-4 W.T. N.T. N.T. N.T.
1(P IL-4 W.T. +++ +++ +
1(P IFN-y W.T. +++ +++ -
1(P IFN-y W.T. +++ ++ +
1(P IFN-y W.T. N.T. N.T. N.T.
1(P IFN-y W.T. ++ + +
1(P IFN-y n .t . ++ + +
KP IFN-y N.T. N.T. N.T. N.T.
1(P IFN-y N.T. N.T. N.T. N.T.
1(P IFN-y N.T. N.T. N.T. N.T.
1(P IFN-y N.T. N.T. N.T. N.T.
10° IFN-y W.T. +++ ++ +
10° IFN-y W.T. ++ ++ +
10° IFN-y W.T. + + -
10° IFN-y W.T. +++ ++ +
10° IFN-y W.T. ++ ++ +
10° IFN-y N.T. ++ ++ +
10° IFN-y N.T. ++ ++ +
10° IFN-y N.T. ++ + +
10° IFN-y N.T. + + +
10° IFN-y N.T. N.T. N.T. N.T.
+ Poor Response ++ Moderate Response +++ Strong Response 
-ve No Response N.T.R.D. - Non-tumour Related Death
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Table 7.4 - Description of Figures 7.1 - 7.6.
Figure Tumour Type Stain Score
7.1
Naive splenocytes + 
control cells CD4+ T-cells +++
7.2
10^ IFN-y N. T.+ 
control cells CD4+ T-cells ++
7.3
Naive splenocytes + 
control cells. CD8+ T-cells ++
7.4
1(P IFN-y N. T.+ 
control cells CD8+ T-cells +
7.5
Naive splenocytes + 
control cells
Haematoxylin + 
Eosin
Well defined tumour 
structure.
7.6
1(P IFN-y N. T.+ 
control cells
Haematoxylin + 
Eosin
Poor tumour 
structure.
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Figu re  7.1 - 5p m  section taken from an animal that received 10^ splenocytes  from a naive  mouse, 
fo l low ed 2 days later with 10^ FS-29 control cells. This section has been stained for C D 4 +  T-cells 
us in g  A E C  as the substrate (red) and Harris 's  haematoxylin  as the countersta in .This  pho tograph  show s 
the s t rong  (+++) C D 4 +  infiltration w hich w as observed in m ost o f  the excised control tum ours.  
x lO  m agnifica tion .
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F ig u re  7.2 - This 5 pm  tum our  section was taken from the only tum our  that deve loped  w hen  anim als 
rece ived  sp lenocytes  from lO^IFN-y treated animals w ho did not develop tum ours.  This  section w as 
also sta ined for C D 4 +  cells and unlike the strong infiltration observed with the control anim als ,  this 
t rea tm en t  p roduced  a m odera te  (++) C D 4+  infiltration. H owever,  as there was only one  sam ple, this 
result canno t  be conclus ive for this treatment. xlO magnification.
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Figure 7.3 - 5 p m  tum our  section taken from an animal that had received 10^ splenocytes  from a naive 
anim al,  fo llow ed 2 days later by 10^ control FS-29 cells. T h is  section, which has been  stained for 
C D 8 +  T-cells, show s that there is a m odera te  (++) C D 8+  infil tration into this tu m o u r  nodule. 
x lO  magnification .
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Figure 7.4 - 5 p m  section taken from an animal that received 10^ splenocytes from an animal that had 
prev iously  received  10^ IFN-y cells and did not develop a tum our. 2 days later this animal received 
10^ FS-29 control cells into the left flank. This section, w hich  has been stained for C D 8 +  cells, show s 
a poor (+) C D 8 +  infiltration into this tumour. H ow ever this canno t be a conclus ive result as only  one 
tu m o u r  deve loped  in this treatm ent group. xlO magnification.
Figure 7.5 - 5 p m  tum our  section taken from an animal that had received 10^ splenocytes  intra- 
peri toneal ly  from a naive animal. 2 days later the animal received 10^ FS-29 control cells into the left 
flank. This haem atoxylin  and eosin stain show s quite well defined structure o f  this tu m o u r  nodule . xlO 
m agnifica tion .
F igure 7.6 - 5 p m  tu m o ur  section taken from an animal that had received 10^ splenocytes  from an 
animal that had previously  received 10^ IFN-y cells and did not develop  a tum our. This  haem atoxylin  
and eosin stain is indicative o f  those an im als  that received splenocytes  from anim als  that had 
p reviously  been given 10^ or 10^ IFN-y cells. O f  the anim als that developed tum ours  they all appeared  
to have a very necrosed, undefined structure  (indicated by arrows). xlO magnification .
8: REGRESSION OF AN ESTABLISHED TIJMOIJR
8.1 Introduction
It has been reported that when genetically altered tumour cells are admixed with 
control tumour cells and injected into animals, tumour growth can be slowed or 
prevented (Patel et al., 1993a, 1993b.). Although these studies examine the ability of 
cytokine-secreting cells to reduce growth of admixes of cells, the ability of cytokine- 
secreting cells to inhibit growth of an already established tumour appears to have been 
examined only once previously. This point seems fundamental in that gene cell 
therapy clinical trials are being carried out in patients with advanced cancer in order to 
regress growth of their primary tumour or of metastatic disease.
Studies have indicated that the effects of cytokine therapy may be enhanced if 
different cytokines are administered in combination (Ohira et al., 1994). The aim of 
this experiment was to examine the ability of the cytokine-secreting cells, alone or in 
various combinations, to regress growth of an already established tumour. Therefore, 
animals were given an injection of control cells into the left flank. One week later the 
mice were also injected into the right flank with the cytokine-secreting cells.
Histological examination of any tumour nodules that formed during the present study 
was also carried out to give an indication as to the effector mechanisms that may be 
implicated in the anti-tumour response.
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8.2 Materials and Methods
This experiment was carried out to assess the ability of the cytokine-secreting cells to 
inhibit the growth of an already established tumour nodule. The control cell-line was 
cultured and harvested as described in section 5.2. The cell density was adjusted to 
give lO^/ml. Fourty-two female immunocompetent C57B1/6 J mice were randomised 
into 8 treatment groups (7 groups of 5, 1 group of 6). Each treatment group received 
1()6 control cells as a lOOpl injection subcutaneously into the left flank using a 26 
gauge needle. One week later the mice received a lOOpl injection subcutaneously of 
control cells or cytokine secreting cells, either alone, or in various combinations, into 
the right flank using a 26 gauge needle. One mouse was killed before it received a 
second injection as it appeared to be in poor health.
Animals were checked daily and tumour growth was measured by palpation between 
the thumb and first finger. When tumours reached approximately 1cm in diameter, the 
animals were killed by neck dislocation. The excised tumours were frozen in liquid 
nitrogen immediately and stored in liquid nitrogen until required for histological 
analysis. Immunohistochemical analysis of the individual tumour sections was carried 
out as detailed in chapter 5. After 28 days the experiment was terminated with the 
death of the last remaining animal.
Statistics: Data are presented as the median and where appropriate, comparisons of 
data from different groups were analysed using the Kruskall-Wallis test which is a 
non-parametric equivalent of analysis of variance (Minitab Inc., Pasadena, CA, 
U.S.A.).
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8.3 Results
Regression of an already established tumour: In this study all of the animals received 
an initial injection of 10^ control cells into the left flank. One week later they were re­
challenged with control cells or cytokine-secreting cells alone or in various 
combinations into the right flank. The results from this study are shown in tables 8.1 
and 8.2. Animals that had received a second injection of control cells all developed 
tumours and were killed on days 14, 16, 17, 17 and 21. The animals injected with IL- 
2-secreting cells had survival rates of 14, 15, 15, 20 and 21 days. The mice treated 
with IL-4-secreting cells also developed tumours which were initially slow-growing, 
but then rapidly reached 1cm. These animals were killed on days 16, 16, 16, 17 and 
20 .
Those animals injected with IFN-y-secreting cells were killed on days 14, 15, 18, 26 
and 28. The animal which survived until day 28 had a tumour but also had another 
tumour growing behind it which was not initially detected. So, the number of days of 
survival in this case should have been less.
When IL-2 and IL-4-secreting cells were administered together, all animals developed 
tumours and were killed on days 12, 17, 17, 18, and 26. All animals developed 
tumours when they received an injection of IL-2 and IFN-y-secreting cells together. 
Animals from this group were killed on days 16, 16, 20, 26 and 27. The last animal 
had a very large tumour which was not easily detectable and should have been killed 
before 27 days.
All animals that received an injection of IL-4 and IFN-y-secreting cells together, 
developed tumours and were killed on days 11, 14, 15, 16 and 19. The final group 
received IL-2, IL-4 and IFN-y cells in one injection. Again all animals developed 
tumours and were killed on days 15, 16, 16, 16, 19 and 20.
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Statistical analysis of this experiment using the Kruskall-Wallis test showed that there 
was no significant differences between groups for the number of days of survival (p = 
0.585).
Immunohistological Analysis: The results are detailed in table 8.3. The animals that 
received a second injection of control cells scored a moderate CD4+ and CD8+ T-cell 
response with a poor B-cell response (Figures 8.1 + 8.3). Animals that received an 
injection of IL-2-secreting cells also scored moderate CD4+ and CD8+ T-cell 
responses with a poor B-cell response.
Those animals treated with IL-4-secreting cells scored a moderate CD4+ T-cell 
response with poor CD8+ T-cell and B-cell responses. An injection of IFN-y-secreting 
cells resulted in a mainly strong CD4+ T-cell response, moderate CD8+ T-cell 
response and a poor B-cell response. Tumours that formed in animals that received 
IL-2 and IL-4-secreting cells scored moderate CD4+ T-cell, CD8+ T-cell and B-cell 
responses. An IL-2 and IFN-y-secreting cell combination scored a moderate CD4+ 
and CD8+ T-cell response with a poor B-cell response.
When IL-4 and IFN-y were injected in combination, the B-cell score was poor but, 
there was a strong CD4+ T-cell infiltration (Figure 8.2) and a moderate CD8"1" T-cell 
response (Figure 8.4). A strong CD4+ T-cell infiltration was observed when IL-2, IL- 
4 and IFN-y-secreting cells were injected in combination. The CD8+ T-cell response 
was moderate and the B-cell response poor.
In this study, there appeared to be little or no peroxidase activity in the different 
treatment groups. The tumour structure in most groups ranged from poor to good. The 
most significant structural difference was in the IL-2 and IFN-y combination group. 
Four of the five tumours appeared to have large necrosed areas in comparison to the 
control group (Figures 8.5 + 8.6).
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8.4 Discussion
The aim of this study was to assess the ability of the cytokine-secreting cells to 
regress growth of an established tumour nodule. The ability of the cytokine-secreting 
cells to perhaps produce additive anti-tumour actions when administered in 
combination was also examined in this study. Animals received 10^ FS-29 control 
cells into the left flank. One week later, the animals received 10^ IL-2-secreting cells 
alone, or in combination with IL-4 or IFN-y-secreting cells into the right flank. It was 
found that the IL-2-secreting cells either alone, or in combination with IL-4 or IFN-y- 
secreting cells could not regress or slow growth of an established tumour nodule. 
Therefore, the combination of cytokine-secreting cells did not result in an enhanced 
anti-tumour response. Patel and co-workers (1993a) reported that when IL-2 and IL-4- 
secreting FS-29 cells were doubly transfected, this combination resulted in an optimal 
tumour rejection when injected into mice. Further evidence of the beneficial effects of 
cytokines administered in combination was reported by Ohira and co-workers (1994). 
He reported that when IL-2 was co-transfected with TNF into the Lewis Lung 
carcinoma and injected into mice, the anti-tumour effects of the co-transfectants was 
superior to that of the IL-2 and TNF transfectants alone. In contrast it has been 
reported that IL-2-secreting FS-29 cells could not prevent growth of an equal number 
of admixed non-secreting FS-29 cells (Patel et al., 1993a). This work is consistent 
with the present study in that the IL-2-secreting FS-29 cells were not able to reduce 
growth of a tumour nodule.
Patel and co-workers (1993a) reported that the tumours that formed from admixtures 
of IL-2-secreting cells and parental cells, had lost their ability to secrete IL-2. It was 
proposed that this loss of secretion may have been due to loss of the IL-2-encoding 
retroviral DNA sequences. Furthermore, a more rapid loss of IL-2 secretion by the FS- 
29 cells was observed when IL-2 and IL-4-secreting cells were admixed and injected 
together into mice. Therefore, it is perhaps unlikely that there was an additive anti­
tumour response when IL-2 and IL-4-secreting FS-29 cells were injected together in
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this study. Histological analysis of the tumour nodules that formed in animals that had 
received IL-2-secreting cells either alone or in combination with IL-4 or IFN-y- 
secreting cells, revealed that these groups had a similar nature of lymphocytic 
infiltration in that they had a moderate CD4+ and CD8+ T-cell response and a poor B- 
cell response. Vaccination of mice with tumour cells engineered to express cytokines 
has been successful in limited cases in causing regression of established tumours. For 
example, it has been reported that IL-2-producing MBT-2 cells could regress growth 
of an orthotopically implanted MBT-2 tumour (Connor et al., 1993).
The ability of the IL-4-secreting cells either alone or in combination with IL-2 or IFN- 
y-secreting cells to reduce growth of an established tumour nodule was also 
investigated. It was found that IL-4-secreting cells alone or in combination with other 
cytokine-secreting cell-lines could not prevent growth of a contralateral tumour 
nodule. Again, it may have been unlikely that the IL-4-secreting cells would be 
capable of regressing growth of an established tumour nodule, since the IL-4-secreting 
cells could not prevent growth of an equal number of non-secreting cells when 
admixed together and injected into mice (Patel et al., 1993a). However, Dranoff and 
co-workers (1993) reported that GM-CSF-secreting B16 melanoma cells could cause 
the rejection of a low inoculum (5 x 10^) of non-secreting B16 melanoma cells. 
Therefore, the size of the primary tumour appears to be important in determining 
whether regression with cytokine-secreting cells is possible.
Examination of the cellular infiltration into tumours that formed during the course of 
the experiment revealed that, IL-4-secreting cells resulted in a moderate CD4+ T-cell 
response with poor CD8+ T-cell and B-cell responses. However there appeared to be a 
stronger lymphocytic infiltration into the tumour nodules that formed when the 
animals received a combination of IL-4 and IFN-y-secreting cells. The B-cell response 
was still poor but, there appeared to be a strong CD4+ T-cell response and a moderate 
CD8+ T-cell response. This strong CD4+ T-cell response was again observed when
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IL-2, IL-4 and IFN-y-secreting cells were injected together. A strong CD4+ T-cell 
infiltration may indicate that the IFN-y and IL-4 combination may enhance the anti­
tumour immune response. There was little peroxidase activity present in these 
tumours which may indicate that macrophage infiltration into the tumours was 
minimal.
The ability of the IFN-y-secreting cells to regress growth of an established tumour 
nodule was also examined in this study. When animals received IFN-y-secreting cells 
alone or in combination with IL-2 or IL-4-secreting cell-lines, growth of the primary 
tumour could not be prevented. It was proposed that the IFN-y-secreting cells may 
reduce tumour growth, as Patel and co-workers (1993b) reported that the IFN-y- 
secreting cells demonstrated significant slowing of growth of an equal number of 
admixed non-secreting cells. However, a tenfold excess of IFN-y-secreting cells 
regressed tumours in only two of the seven tested animals. In the present study, 
animals received 10^ control cells followed one week later by 10^ IFN-y-secreting 
cells. Therefore, perhaps this study should be repeated using at least a tenfold increase 
in the quantity of cytokine-secreting cells.
Examination of the cellular infiltration into the tumours that formed in the animals 
that had received IFN-y-secreting cells alone, revealed that there was a strong CD4+ 
T-cell response, moderate CD8+ T-cell response and a poor B-cell response. When 
IFN-y and IL-2-secreting cells were injected together a moderate CD4+ and CD8+ T- 
cell response and a poor B-cell response was observed. Furthermore, in the tumours 
that formed in the animals that had received an IL-2 and IFN-y-secreting cell 
combination, four of the five tumours had large necrotic areas. This may indicate that 
the combination of the effector mechanisms in this group may lead to a more 
destructive anti-tumour response. There was little peroxidase activity in any of the 
groups which may indicate that macrophages were not a main effector mechanism 
involved in the immune response.
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From the present study, it appears that the cytokine-secreting cell-lines cannot regress 
growth of an established tumour nodule. When the cytokine-secreting cells were 
injected in various combinations into mice, there did not appear to be any additive 
interactions that could enhance regression of the primary tumour nodule. However, 
there did appear to be an enhanced overall lymphocytic infiltration and extensive 
necrosis of the primary tumour nodule with some cytokine combination treatments. 
Results from other studies indicates that the original tumour burden is important in 
determining whether regression of the primary tumour will take place. Therefore, a 
more appropriate method of using these cytokine-secreting cells may be to inject the 
cells into animals when the primary tumour has been excised in order to prevent 
growth of residual tumour cells. Furthermore, administration of the cytokine-secreting 
cells in various combinations may enhance the cellular infiltration into the tumour 
resection area and therefore promote a more vigorous anti-tumour response.
106
Table 8.1: Regression of an Established Tumour
Animal
No.
Control IL-2 IL-4 IFN-y
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
1 16 12.3x7.5 15 12.8x5.9 16 ascitic 15 8.6x6.6 
9.8x6.5
2 17 6.7x10.0 21 10.1x8.4 17 9.2x8.3 14 10.9x4.6
3 21 9.7x8.3 15 10.0x6.6 20 5.2x4.1 
8.8x5.2
28 1.1x62
42x4.6
4 17 ascitic 20 9.2x5.2 
6.1x5.0
16 ascitic 26 10.8x 
12.9 
l . l x l . 5
5 14 ascitic 14 6.6x4.1 
8.2x6.4
16 ascitic 18 7.2x8.3
Median 17 15 16 18
Table 8.2: Regression of an Established Tumour
A n im al
No.
IL-2/IL-4 IL-2/IFN-y IL-4/IFN-y IL-2/IL-4/IFN-y
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
Survival
(Days)
Tumour
Size
(mm)
1 17 7.2x10.1 16 ascitic 19 3.3x3.2 
1.Ox 1.0 
ascitic
15 12.7x4.1
13x5.6
2 17 4.0x6.0 
4.1x5.6 
ascitic
16 ascitic 11 11.9x5.5 20 7.6x3.3 
6.4x4.2 
ascitic
3 18 9.9x7.4 20 13x5.1
10.7x8.0
ascitic
15 8.7x7.5 16 10.4x7.9
4 12 ascitic 26 14.4x
11.8
ascitic
16 ascitic 19 11.1x5.2
5 26 12.3x
11.5
27 8.2x8.1 
8.9x8.5
14 3.4x13.5 16 8.6x6.9 
5.8x4.5
6 16 10.3x6.8
Median 17 20 15 16
N.T. - No Tumour.
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Table 8.3 - Histological Analysis
Treatment CD4 CD8 B220
Control + Control +++ +++ +
Control + Control ++ ++ +
Control + Control ++ + +
Control + Control ++ ++ +
Control + Control ++ ++ +
Control + IL-2 +++ ++ +
Control + IL-2 ++ ++ +
Control + IL-2 ++ ++ +
Control + IL-2 ++ + +
Control + IL-2 ++ + +
Control + IL-4 ++ + +
Control + IL-4 ++ ++ +
Control + IL-4 ++ + +
Control + IL-4 ++ + +
Control + IL-4 + + +
Control + IFN-y +++ +++ +
Control + IFN-y +++ ++ +
Control + IFN-y + + +
Control + IFN-y ++ ++ ++
Control + IL-2/IL-4 ++ ++ +
Control + IL-2/IL-4 + ++ +
Control + IL-2/IL-4 ++ + +
Control + IL-2/IL-4 ++ + +
Control + IL-2/IL-4 ++ ++ +
Control + IL-2/IFN-y ++ ++ +
Control + IL-2/IFN-y +++ +++ +
Control + IL-2/IFN-y + + +
Control + lL-2/IFN-y ++ + +
Control + IL-2/IFN-y +++ ++ +
Control + IL-4/IFN-y +++ +++ ++
Control + IL-4/IFN-y +++ +++ +
Control + IL-4/IFN-y +++ ++ +
Control + IL-4/IFN-y ++ ++ +
Control + IL-4/IFN-y ++ + +
Control + IL-2/lL-4/IFN-y +++ +++ ++
Control + IL-2/IL-4/IFN-y +++ ++ +
Control + IL-2/IL-4/IFN-y +++ ++ +
Control + IL-2/IL-4/IFN-y +++ ++ +
Control + IL-2/IL-4/IFN-y + + -
Control + IL-2/IL-4/IFN-y + + +
+ Poor Response. ++ Moderate Response. +++ Strong Response.
- No Response
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Table 8.4 - Description of Figures 8.1 - 8.6.
Figure Tumour Type Stain Score
8.1 Control cells CD4+ T-cells ++
8.2 IL-4 +IFN-y cells. CD4+ T-cells +++
8.3 Control cells CD8+ T-cells ++
8.4 IL-4 +IFN-y cells. CD8+ T-cells ++
8.5 Control cells
Haematoxylin + 
Eosin
Well defined tumour 
structure.
8.6 IL-2 +IFN-y cells.
Haematoxylin + 
Eosin
Poor tumour 
structure.
109
Tigure 8.1 - 5 p m  section o f  tum our taken from an animal that had received 10^ control FS-29 ceils into 
he left flank, fo llow ed 7 days later with 10^ control cells into the right flank. This section has been 
;tained for C D 4+  T-cells using  A EC  as the substrate and Harris's haem atoxylin  as the counterstain . T he  
photograph show s that there  is a m odera te  (++) C D 4 +  infiltration into the tum our  nodule.
<10 magnification.
• f
7igure 8.2 - 5 pm  tum our  section taken from an animal that had received 10^ control cells into the left 
lank, fo llow ed 7 days later with 10^ IL-4/IFN-y FS-29 cells into the right flank. U se  o f  this cytokine 
ombination  resulted in a s trong (+++) C D 4+  infiltration into the tu m o u r  nodule. x lO  magnification.
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Figure 8.3 - 5 p m  section from a tum our  nodule excised from an anim al that received an injection o f  
10^ control FS-29 cells, followed one week later with 10^ control cells into the right flank. This 
sam ple  w as stained for C D 8 +  T-cells using A EC  as the substrate and Harris's haem atoxylin  as the 
countersta in .  The  control cells induced a moderate  (++) C D 8+  response into the tumour, 
x 10 m agnification .
F igure 8.4 - 5 p m  tum our  section from an animal that had received 10^ control cells into the left flank 
fo l low ed one w eek  later with 10^ IL-4/IFN-y secreting FS-29 cells into the right flank. With this 
cy tok ine  combination  there appears to be an overall s tronger (+++) C D 8+  T-cell response  into the 
tum our.  x lO  magnification .
Figure 8.5 - H aem atoxy lin  and eosin staining o f  a tum our  excised from an animal that had received 
10^ co n tro l  FS-29  cells into the left flank, followed 7 days later with an injection o f  10^ control cells 
into the right flank. This  5 pm  section o f  tum our shows a well defined structure with no necrosed  areas, 
x 10 m agn if ica tion .
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Figure 8.6 - H aem atoxy lin  and eosin staining o f  a tum our excised from an animal that had received an 
initial injection o f  10^ control FS-29 cells into the left flank, fo llow ed by 10^ IL -2/ lFN -y secreting  FS- 
29 cells into the  right flank. The structure o f  this tu m o ur  is very poor in com par ison  to the control. 
T here  are large areas that appear  to be necrosed tissue (indicated by the arrows), x 10 magnifica tion
9: Conclusion
In section 3.12 the aims of this thesis were defined as follows;
9.1 Aim 1
This was to address the following questions in an animal tumour model. When 
animals are given a two-site injection of cells is there a systemic anti-tumour reaction 
that prevents growth of the tumour cells at both sites and is this systemic protection 
dependant on the cytokine that the tumour cell secretes? Furthermore, is the ability to 
promote systemic protection dependant on the tumour burden?
What are the possible effector mechanisms involved in the anti-tumour response in 
this study?
There have been several attempts over the years to exploit cytokines as an 
immunotherapeutic treatment for cancer. However, success with cytokines has been 
limited mainly due to the toxic side-effects of these compounds. Therefore, several 
other routes of administration have been employed in an attempt to reduce toxicity 
and improve efficacy with various degrees of success (Retsas et al., 1989; Hill et al., 
1994). It was the first successful cytokine gene cell therapy study by Tepper and co­
workers in 1989 that triggered more studies into the effectiveness of rendering tumour 
cells more immunogenic by enabling them to secrete cytokines. The aim of the first 
study was to further assess the growth rates of the FS-29 cell-line which has been 
engineered to secrete cytokines (Chapter 6). The animals in this study received a two- 
site injection of either 10^ or 10^ control FS-29 cells or cytokine-secreting cells into 
each flank. It was observed that the IL-2-secreting cells did not grow more slowly in 
either the 10^ or 10^ cell injection groups. However, this cell-line appeared to induce 
a stronger T-cell response than the non-secreting cells into the tumour nodules that 
formed but, this infiltration did not promote an effective anti-tumour response. The 
IL-4-secreting cells grew significantly slower than the non-secreting cells, however 
this was only in the animals that received the larger tumour cell number. Histological 
analysis of the tumour nodules that formed in the IL-4 treatment group revealed that
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there was a moderate T-cell infiltration into the tumour nodule. Furthermore, the 
tumour nodules that formed from the IL-4-secreting cells appeared to have a strong 
infiltration of peroxidase-positive cells into the tumour nodule, which may be 
macrophages and therefore, macrophages may be an important effector mechanism in 
the IL-4 anti-tumour response. The IFN-y-secreting cells grew significantly slower 
than the control cells but, again this was only in the animal treatment group that had 
received 10^ cells. As there were only two tumours that formed in the IFN-y treatment 
group, little indication of the effector mechanisms that may be involved in the IFN-y 
anti-tumour response could be gained. However, T-cells may be an important effector 
mechanism as there was a moderate infiltration of CD4+ and CD8+ T-cells into these 
tumour nodules. Therefore, from this work it would appear that the IFN-y and the IL- 
4-secreting FS-29 cells but, not the IL-2-secreting FS-29 cells, demonstrate reduced 
tumourigenicity in vivo. Furthermore, it would appear that large numbers of cytokine- 
secreting cells are required for an effective anti-tumour response and that the possible 
effector mechanisms involved in the anti-tumour response remain unclear.
9.2 Aim 2
This was to address whether animals that have previously received secreting or non­
secreting cells, which then grew slowly or did not grow at all, transfer immune 
memory to a naive animal and therefore protect against a subsequent tumour 
challenge?
Furthermore, what are the possible effector mechanism involved in the transfer of 
anti-tumour immune memory between animals?
It has been reported that when animals have rejected a challenge with cytokine- 
secreting cells and have subsequently rejected a challenge of non-secreting cells that 
this protective response appeared to correlate with tumour-specific cytotoxic T-cells 
in the spleens of these animals (Gansbacher et al., 1990a). This study was carried out 
to assess the ability of tumour-specific T-cells to transfer anti-tumour memory
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between animals (Chapter 7). Unfortunately none of the animals that had received 
either cytokine-secreting or control FS-29 cells appeared to transfer anti-tumour 
protection to naive animals. However, the treatment groups were small in this study 
and as some of the animals did reject tumour growth, it may be that further studies 
with larger animal group numbers may give a better indication as to the potential of 
splenocyte transfer.
It was of interest that the group that received \Qp splenocytes from an animal that had 
previously received 10^ IFN-y-secreting cells and had not developed a tumour, 
demonstrated slower tumour growth rates when challenged with 10^ control FS-29 
cells. Only one of the four animals developed a small slow growing tumour in this 
treatment group. However, the animals that received splenocytes from an animal that 
had previously received 10^ IFN-y-secreting cells and did not develop a tumour had 
more animals in this group developing tumours, with four of the five animals 
developing tumours. Therefore, this study suggests that the original tumour burden of 
the animal may be important when determining whether splenocyte transfer is capable 
of transferring anti-tumour memory. Little information has been gained as to the 
effector mechanisms that may be involved in the transfer of anti-tumour memory as 
only one tumour formed in the most successful group. However, there was a moderate 
CD4+ T-cell infiltration and a poor CD8+ T-cell infiltration into this tumour nodule.
9.3 Aim 3
This was to address whether the cytokine-secreting cell-lines are able to slow or 
regress growth of an already established tumour? Furthermore, are there any additive 
or antagonistic interactions of the cytokine secreting cells when administered in 
various combinations?
What are the effector mechansim involved in regressing growth of an established 
tumour nodule and is the inflammatory infiltration enhanced or reduced when 
cytokines are administered together?
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It has been reported that when cytokine-secreting tumour cells are admixed with 
control tumour cells and injected into animals, tumour growth may be slowed or 
prevented (Patel et al., 1993a, 1993b). Studies have indicated that the efficacy of 
cytokine gene therapy may be enhanced if cytokines are administered in combination 
(Ohira et al., 1994). However, in the present study none of the IL-2, IL-4 or IFN-y- 
secreting cell-lines either alone or in various combinations was capable of regressing 
growth of an established tumour nodule (Chapter 8). However, there did appear to be 
an overall stronger T-cell infiltration into the tumour nodules that formed when the 
IL-4-secreting cells and the IFN-y-secreting cells were administered together. The 
present study and the work reported by Patel and colleagues (1993a, 1993b) indicates 
that the initial tumour burden is important in determining the extent of the anti-tumour 
response, in that cytokine-secreting cells are capable of reducing growth of an equal 
number of admixed tumour cells at most. Patel and colleagues (1993b) reported that 
the IFN-y-secreting cells had to be present in a tenfold excess in comparison to the 
control cells in order for complete tumour regression to take place. Therefore, it is 
likely that a large number of cytokine-secreting cells would have to be administered in 
order to regress tumour growth in humans and in particular those with advanced 
disease.
From the present studies and those of Patel and co-workers (1993a and 1993b) it can 
be concluded that the IFN-y-secreting FS-29 cells are capable of producing a more 
effective anti-tumour response in comparison to that of the IL-2 or IL-4-secreting 
cells. However, it is not known which effector mechanism is responsible for the anti­
tumour response, whether it be cytotoxic lymphocytes or macrophages. Clearly, 
experimental work to determine this effector mechanism is required and such 
information may enable the development of the optimum anti-tumour response in this 
animal model.
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9.4 Clinical Studies Using Cytokine Gene Cell Therapy 
Although the animal studies using cytokine gene modified tumour cells are 
encouraging, there are a number of considerations that have to be taken into account 
that will determine whether this approach to cancer therapy will have value in clinical 
trials. For example most human tumours are difficult to establish as cell-lines and 
autologous cell lines will have to be established from each patient to be treated. There 
is also the problem that after extended passage, the antigenic composition of the 
tumour cell may change in comparison to the primary tumour from which the cell 
originated. Once the patients cell-line has been generated, high efficiency gene 
transfer systems are required to genetically alter these primary tumour cell-lines. 
These systems must be capable of consistently transferring the gene into the cell and 
must also allow the continual expression of the cytokine. The use of retroviral vectors 
appears to overcome some of these problems, and may allow efficient gene transfer 
into primary tumour explants (Jaffee et al., 1993).
Future vaccination of patients with cytokine-secreting tumour cells will require 
methods to prevent tumour formation by gene-modified tumour cells in vivo. 
However, it is important that any procedures used should not diminish the capability 
of gene-modified tumour cells to secrete cytokines, and should not abolish their 
immunogenicity. High dose y-irradiation has been successfully tested in some cell 
lines. Dranoff and co-workers (1993) reported that GM-CSF-secreting melanoma cells 
were still effective at stimulating potent, long-lasting and specific anti-tumour 
immunity when irradiated. When the renal cancer cell line, SK-RC-29, was irradiated, 
growth of the cytokine gene-modified cells was prevented in vivo, and their ability to 
release cytokines and express antigenic determinants, such as HLA-DR, appeared to 
be unaffected (Gastl et al 1992).
A problem of this new type of therapy is that these cytokine-secreting cells may be 
given to patients with advanced disease when established chemotherapy regimens
114
have failed. If this is the case it would appear likely that the tumour burden will be too 
large for the cytokine-secreting cells to have a measurable effect. Therefore, it may be 
that the most efficacious regimen for this type of therapy is to administer cytokine- 
secreting cells to patients who have received their primary surgery, in order to 
eradicate any remaining local disease.
This present study and that of Patel and co-workers (1993b) indicates that IFN-y- 
secreting tumour cells may be an effective anti-tumour therapy. Previous clinical trials 
administering IFN-y subcutaneously to metastatic renal cancer and non-small cell lung 
cancer patients demonstrated varied clinical responses and were associated with 
severe toxicity (Weiner et al., 1994; Shaw et al., 1995). Therefore, it is hoped that the 
use of cytokine-secreting tumour cells may increase the efficacy and reduce the 
toxicity associated with IFN-y. A trial using IFN-y-secreting tumour cells for the 
treatment of metastatic melanoma is underway and it is hoped that the clinical results 
will have similar success to that of the animal studies (Seigler et al., 1994). From the 
literature it would appear that such studies in cancer patients are in their infancy, and 
it may be some time before the therapeutic merits of cytokine gene cell therapy are 
known.
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